
    PHARMASTEM THERAPEUTICS, INC., Plaintiff-Appellant, v. VIACELL, INC., Defendant-Cross Appellant, and Cryo-Cell International, Inc., CorCell, Inc., Defendants-Cross Appellants, and CBR Systems, Inc. (formerly known as Cord Blood Registry, Inc.), Defendant-Cross Appellant, and Birthcells Technology, Inc. and Bio-Cell, Inc., Defendants.
    Nos. 05-1490, 05-1551.
    United States Court of Appeals, Federal Circuit.
    July 9, 2007.
    
      Paul J. Andre, Perkins Coie, LLP, of Menlo Park, CA, argued for plaintiff-appellant PharmaStem Therapeutics, Inc. With him on the brief was Lisa Kobialka.
    John C. Englander, Goodwin Procter LLP, of Boston, MA, argued for defendant-cross appellant ViaCell, Inc. With him on the brief were Paul F. Ware, Jr. and Elaine Herrmann Blais. Of counsel on the brief was Richard M. Wyner, of Washington, DC.
    James J. Rodgers, Dilworth Paxson LLP, of Philadelphia, PA, argued for defendants-cross appellants Cryo-Cell International, Inc., et al. Of counsel was Evelyn H. McConathy, Drinker Biddle & Reath LLP, of Philadelphia, PA.
    Thomas F. Chaffin, Pillsbury Winthrop Shaw Pittman LLP, of Palo Alto, CA, argued for defendant-cross appellant CBR Systems, Inc. With him on the brief was William F. Abrams. Of counsel on the brief were Guillermo E. Baeza, of McLean, VA, and Kevin M. Fong, of San Francisco, CA.
    Before NEWMAN, BRYSON, and PROST, Circuit Judges.
   Opinion for the court filed by Circuit Judge BRYSON. Dissenting opinion filed by Circuit Judge NEWMAN.

BRYSON, Circuit Judge.

This patent infringement action was brought by appellant PharmaStem Therapeutics, Inc., in the United States District Court for the District of Delaware. Phar-maStem sued six defendants (four of which are appellees before us in this appeal), alleging that the defendants had infringed two patents owned by PharmaStem, U.S. Patent No. B1 5,004,681 (“the '681 patent”) and U.S. Patent No. 5,192,553 (“the '553 patent”), a continuation-in-part of the '681 patent. At the conclusion of the trial, the jury returned verdicts for PharmaStem on both patents, finding both patents infringed and not invalid. The jury also rejected the defendants’ counterclaims of inequitable conduct and violation of the antitrust laws.

The defendants filed motions for judgment as a matter of law (“JMOL”) and a new trial. In response, the district court initially entered an order granting a new trial on the issue of infringement of the ’681 patent and JMOL of noninfringement as to the '553 patent. Subsequently, however, the court vacated the new trial order as to the '681 patent and instead entered JMOL of noninfringement as to that patent. The court denied the defendants’ JMOL motions with respect to various asserted grounds of patent invalidity. Phar-maStem now appeals from the JMOL orders on infringement, and the defendants cross-appeal from the court’s refusal to grant JMOL on invalidity. We affirm the district court’s judgment as to the infringement issues. With respect to the counterclaim of invalidity for obviousness, however, we reverse the judgment and direct the entry of judgment for the defendants.

I

The two patents in suit recite compositions and methods relating to a medical procedure for treating persons with compromised blood and immune systems. The treatment is based on the discovery that blood from a newborn infant’s umbilical cord is a rich source of a type of stem cells useful for rebuilding an individual’s blood and immune system after that system has been compromised by disease or a medical treatment such as chemotherapy.

Stem cells are fundamental (or “immature,” or “primitive”) cells from which specialized (or “mature”) cells derive. Hema-topoietic stem cells are stem cells that are ultimately responsible for producing the various specialized cells of the blood and immune (or “hematopoietic”) system. He-matopoietic stem cells produce progenitor cells and more hematopoietic stem cells. The progenitor cells, which are less primitive than the stem cells, in turn give rise to the variety of specialized cells that constitute the blood and immune system.

Although hematopoietic stem cells are present in various types of human tissue, they are found in unusually high concentration and potency in umbilical cord blood. The '681 and '553 patents describe a process for collecting a newborn infant’s umbilical cord blood at the time of birth, testing it for suitability for later use, preserving it through cryopreservation, and infusing it into an individual (either the donor or another person, preferably one with a closely matched blood type) whose hematopoietic stem cells have been destroyed. The object of such transplanta-tions is to effect grafting. A successful graft results when the donor’s stem cells migrate into the recipient’s bone marrow, resulting in the renewed production of normal, specialized blood cells and ultimately the reconstitution of the recipient’s entire blood and immune system.

As issued, the '681 patent contained very broad claims. Claim 1 recited a composition comprising “a plurality of viable human neonatal or fetal hematopoietic stem cells derived from the blood [and a] cryopreservative.” In reexamination, several of the original claims were cancelled. Claim 1 was amended to read as follows:

A cryopreserved therapeutic composition comprising viable human neonatal or fetal hematopoietic stem cells derived from the umbilical cord blood or placental blood of a single human collected at the birth of said human, in which said cells are present in an amount sufficient to effect hematopoietic reconstitution of a human adult; and an amount of cryo-preservative sufficient for cryopreservation of said cells.

Claim 2, which is dependent on claim 1, was amended to recite the composition of claim 1 “which further comprises viable human neonatal or fetal hematopoietic progenitor cells.”

Each of the defendants offers a service to families of newborn infants in which blood from the infant’s umbilical cord is collected and cryopreserved for possible later use. The defendants represent in their promotional literature that the preserved cord blood may be useful for reconstituting the donor’s hematopoietic system in the event that system is damaged or destroyed as a result of disease or other causes. Some of the promotional literature advises that the preserved cord blood may also be useful for treating closely related members of the infant’s family.

In the infringement action brought against all six defendants, PharmaStem asserted claims 1 and 2 of the '681 patent, as amended in reexamination, and claims 13, 19, 47, 53, and 57 of the '553 patent. Claims 13, 47, and 57 of the '553 patent are independent claims. Claim 13 provides as follows:

A method for hematopoietic or immune reconstitution of a human comprising:
(a) isolating human neonatal or fetal blood components containing hemato-poietic stem cells;
(b) cryopreserving the blood components;
(c) thawing the blood components; and
(d) introducing the blood components into a suitable human host, such that the hematopoietic stem cells are viable and can proliferate with the host.

Claim 47 is similar except that it refers to the blood components “containing hemato-poietic stem and progenitor cells.” Dependent claims 19 and 53 add that the blood components are isolated by collection from an umbilical cord. Independent claim 57 provides as follows:

A method for hematopoietic or immune reconstitution of a human comprising introducing into the human a composition comprising human neonatal or fetal hematopoietic stem cells derived from the blood, in which the stem cells have been previously cryopreserved.

II

Following the jury’s verdict finding infringement of both patents by all four appellants, the district court granted the defendants’ JMOL motions and entered a judgment of noninfringement with respect to both patents. The court agreed with the defendants that, in light of the legal theories pressed by PharmaStem at trial, the evidence failed to show that any of the defendants had infringed any of the asserted claims of either patent in suit.

As to infringement of the asserted '681 patent claims, the district court focused on the requirement that the recited compositions contain stem cells “in an amount sufficient to effect hematopoietic reconstitution of a human adult.” To prove infringement, the court explained, PharmaS-tem was required to adduce evidence that the defendants’ cord blood units contained a sufficient supply of stem cells to effect successful reconstitution of an adult. The court concluded that PharmaStem had failed to do so.

In addressing the sufficiency of the evidence on that issue, the trial court first ruled that it should have excluded the trial testimony of Dr. Mary Hendrix, PharmaS-tem’s expert witness on infringement. The court noted that although Dr. Hendrix was “an accomplished stem cell biologist,” she based her infringement opinion “entirely on an analysis of the defendants’ marketing materials, without ever considering any data regarding the composition of the defendants’ cord blood units.” The court explained that Dr. Hendrix was not qualified as an expert in marketing or advertising and, in any event, “her so-called analysis of the defendants’ marketing materials was well within the jury’s common knowledge, common sense and common experience.” The court pointed out that Dr. Hendrix’s opinion that all of the defendants’ cord blood units infringe was based on her conclusion that the defendants’ promotional materials “promise stem cells for pediatric and adult transplantation.” In that respect, according to the court, “her opinion of infringement is no more than a lay-person’s interpretation of the defendants’ marketing materials.” The court therefore ruled that her testimony should have been excluded and that “permitting PharmaStem to couch its presentation of this evidence in the form of an expert opinion was an error.”

The district court then pointed out that the evidence at trial overwhelmingly indicated that not all units of cord blood obtained from a single individual at birth contain enough stem cells to reconstitute an adult. The court explained that Phar-maStem did not attempt to prove by testing or by reference to data collected by the defendants that at least some of the cord blood samples preserved by the defendants satisfied that requirement. Instead, the court noted, PharmaStem adopted the strategy of trying to prove, principally through representations made by the defendants in their marketing materials and other documents, that all of the preserved cord blood samples infringed. As a consequence, the court explained, PharmaStem “presented no evidence to the jury from which it could conclude that any specific cord blood unit or units stored by any of the defendants contained stem cells in a sufficient amount to reconstitute a human adult.” Because there was “no legally sufficient evidentiary basis for a reasonable jury to find that all, or any specific number, of the defendants’ cord blood units infringe the '681 patent,” the court granted the defendants’ motion for JMOL as to the '681 patent claims.

As to infringement of the '553 patent, the district court granted the defendants’ motions for JMOL because it concluded that PharmaStem had failed to prove that the defendants were guilty of contributory infringement, which was PharmaStem’s theory of liability. Under the court’s instructions, the jury was required to answer three questions in the affirmative in order to find that any of the defendants contributorily infringed the '553 patent. Specifically, the jury was required to find (1) that eryopreserved cord blood has no substantial noninfringing uses; (2) that the defendants and transplant physicians were acting in concert or working together to complete the process of infringement of the asserted claims of the '553 patent; and (3) that the defendants contributorily infringed “by selling or offering to sell eryopreserved cord blood that was actually used by a third party in the direct infringement” of the asserted claims. The court held that there was sufficient evidence at trial to support the jury’s affirmative answers to the first two questions. With respect to the third question, however, the court held that there was no evidence in the record to support the jury’s affirmative answer. The court explained its ruling as follows:

It is undisputed that the defendants do not own the cord blood units. Rather the units are owned by the clients, or families, and the defendants in turn provide services with respect to the processing and storing of the compositions. Although the defendants charge enrollment, processing, and banking fees with respect to their storage services, they do not sell or offer to sell the cord blood units. Indeed, the record evidence on this issue is clear that the defendants sell a service, not cord blood units.

Because the court ruled that liability for contributory infringement “is clearly dependent upon the accused infringer’s selling or offering to sell a component of the patented process, here cord blood units,” the court held that the jury’s verdict could not stand. The court therefore granted JMOL as to the asserted claims of the '553 patent.

Although granting the defendants’ motions for JMOL as to infringement, the district court denied their motions for JMOL of invalidity with respect to the asserted claims. As to obviousness, the court ruled that the evidence at trial showed that there wei*e problems associated with the use of other transplant tissues, such as bone marrow and adult blood, and that there was “tremendous skepticism in the transplant field regarding the use of cord blood as a transplant tissue.” Although the court stated that a jury could have found from the evidence that the asserted claims would have been obvious, the court ruled that the evidence was sufficient to entitle the jury to conclude that “prior to the inventions of the Patents-In-Suit, those in the field of hematopoietic reconstitution would not have expected cord blood to be a successful transplant tissue.”

As to anticipation, the district court again ruled that the evidence was sufficient to support the jury’s verdict that the prior art reference on which the defendants relied did not anticipate the asserted claims. The court explained that the jury was entitled to find that the prior art reference did not prove that there were stem cells in umbilical cord blood, and that the jury could reasonably have concluded that the suggestion of introducing stem cells into a human host was not “a sufficiently enabling disclosure to warrant a finding of anticipation.”

Finally, the district court rejected the defendants’ argument that the '681 patent was invalid for indefiniteness. The court acknowledged that claim 1 of the '681 patent does not specify a particular number of cells or volume of blood that is required to infringe. Nonetheless, the court concluded that “the record supports that the '681 Patent’s claim language is as precise as the subject matter permits.” Moreover, the court ruled that the record contained evidence establishing that “a person of skill in the art would have understood what an amount of cord blood stem cells sufficient to effect hematopoietic reconstitution of a human adult means.”

PharmaStem has appealed from the portion of the district court’s judgment granting JMOL of noninfringement with respect to both patents. The defendants have cross-appealed from the portion of the judgment upholding the jury’s verdict that the two patents are not invalid on grounds of anticipation, obviousness, or (in the case of the '681 patent) indefiniteness.

Ill

With respect to infringement of the '681 patent, the dispute on appeal is a narrow one. The only contested limitation of the asserted claims is the limitation requiring that the claimed composition contain neonatal or fetal hematopoietic stem cells “in an amount sufficient to effect hematopoietic reconstitution of a human adult.” Phar-maStem contends that all of the cord blood samples the defendants have preserved infringe claim 1 of the '681 patent because the evidence at trial was sufficient to show that all those cord blood units contained enough stem cells to effect the hemato-poietic reconstitution of a human adult. The defendants contend that PharmaStem failed to prove that any of their cryopre-served samples satisfy that limitation.

As the district court noted, PharmaStem did not attempt to use direct testing or other scientific evidence to prove that any particular cord blood sample or group of samples preserved by any of the defendants contained enough stem cells to reconstitute a human adult. Instead, Phar-maStem relied on indirect evidence in the form of advertising and other materials generated by the defendants, scientific evidence relating to stem cell research in general, testimony from representatives of the defendants, and testimony by their own expert witness, Dr. Hendrix. The district court, however, concluded that PharmaStem’s evidence did not constitute substantial evidence in support of Phar-maStem’s theory of infringement.

A

The trial court was correct in ruling that the evidence of the defendants’ advertising and other materials did not provide a sufficient basis for a finding of infringement. That evidence consisted of various statements by each of the defendants that the cord blood samples they preserved could be potentially useful not only for the donor but also for the donor’s relatives, including adult relatives.

To be sure, there is no prohibition against using the admissions of a party, whether in the form of marketing materials or otherwise, as evidence in an infringement action; such admissions are entitled to weight along with all other evidence of infringement. In this case, however, while the defendants’ statements touted the possible therapeutic uses the cord blood might have for the child and members of the child’s family in the future, none of the statements represented that the stem cells in any of the cryopre-served cord blood samples were sufficient in number to effect hematopoietic reconstitution of an adult, as is required by claim 1 of the reexamined '681 patent. Instead, the defendants’ statements emphasized the potential therapeutic usefulness of the cord blood in general and referred to future uses of stored blood in adult transplants only as possibilities.

For example, PharmaStem introduced a statement from a website maintained by defendant CBR Systems, Inc., which referred to the number and character of cord blood transplants worldwide as of that time. The statement recited that “umbilical cord blood has been used in more than 2,500 transplants by children and adults. In many cases, the cord blood was used by the baby’s sibling. Other transplants have occurred for the newborn himself, the newborn’s mother, father, and the newborn’s cousin.” With respect to its own preserved cord blood units, CBR stated that it had provided “over two dozen samples for use in transplantation,” that most have been used for siblings, but that in one instance the newborn’s “cord blood stem cells were transplanted to her mother to treat chronic myelogenous leukemia.”

Those statements fall short of proving that any (much less all) of CBR’s cord blood samples contained enough stem cells to reconstitute an adult. The first statement simply recited that among the 2500 world-wide transplants, some had been conducted on adults. The second statement reflected that one such adult transfer was attempted with a CBR cord blood sample. Neither statement made any representation whether or to what extent the particular transplants had succeeded in reconstituting the adults’ hematopoietic systems. Nor did the specific reference to the one adult transplant represent that the transplant was successful or that only a single unit of cord blood was used in the transplant. Those gaps in the proof are significant, because the evidence showed that as of the time of trial the great majority of all cord blood transplants worldwide had been for the treatment of children. In addition, the evidence showed that in most cases involving adult transplantations, the transplant physicians had used two units of cord blood, not the one unit obtained at the time of a single birth. Uncontradicted evidence at trial showed that two units were used because in most cases the physicians regarded a single unit as insufficient for an adult transplantation.

PharmaStem introduced similar statements from defendant CorCell, Inc. In particular, PharmaStem pointed to a statement in CorCell’s promotional literature that if cord blood could be saved, “it would be a perfect match for the donor, but could also provide life saving benefits for siblings, and other family members.” Several other statements by CorCell were to the same effect — that cord blood could potentially be of benefit not only to the child but also to other members of the child’s family. As in the case of CBR, however, those statements did not constitute representations that single units of CorCell’s preserved cord blood would contain a sufficient number of stem cells to reconstitute an adult. PharmaStem notes in passing that one sample of CorCell’s preserved cord blood was used in an adult transplantation, but the evidence at trial showed that the adult transplant did not graft and the patient died. Accordingly, that evidence provides no support at all for Phar-maStem’s theory of infringement.

With respect to defendant Cryo-Cell International, Inc., PharmaStem again introduced statements from the company’s website that cord blood is a source of stem cells for the child or “possibly” other family members. PharmaStem’s expert witness, Dr. Hendrix, interpreted that statement to refer to adult family members and to constitute a representation that each unit of cord blood preserved by Cryo-Cell contains enough stem cells to reconstitute an adult. The statements about possible use for other family members, however, do not amount to representations that any single stored unit would be sufficient by itself to reconstitute an adult, much less that all of the samples have that capacity.

Similarly, PharmaStem introduced evidence that defendant ViaCell, Inc., had advertised that cord blood could be stored “for potential use by a sibling, parent, first cousin or the newborn itself.” While Via-Cell’s promotional materials stated that cord blood had been used in adult transplantation efforts, PharmaStem points to no representation by ViaCell that a single unit of its stored cord blood had ever been successfully used to effect hematopoietic reconstitution of an adult.

B

In addition to the evidence of the defendants’ statements, PharmaStem also relied on evidence that each of the defendants tested their cord blood samples before cryopreserving them. Like the defendants’ statements, however, that evidence also failed to establish that the preserved samples contained sufficient numbers of stem cells to effect hematopoietic reconstitution of an adult. The testing evidence showed that the defendants used various means to screen the cord blood samples before submitting them for eryopreservation. Those tests included determining whether the samples contained more than a minimum volume of blood, whether the samples were free of contamination, and whether they contained a minimum number of viable nucleated cells. Each of those -testing measures was designed to increase the likelihood that the cord blood units contained viable stem cells and could be therapeutically useful. That evidence did not show, however, that the testing excluded all samples that lacked the capacity to reconstitute an adult, because there was no showing that the defendants chose to preserve only those samples that contained sufficient stem cells for adult reconstitution, much less that their testing procedures had that effect. Nor did Phar-maStem argue that the defendants’ tests could be used to show that some subset of all of the preserved samples contained enough stem cells to reconstitute an adult. To the contrary, the evidence showed that the defendants saved cord blood samples when the defendants thought the samples might be of some potential therapeutic use, which would include transplantation of an infant or a young child.

C

In its brief on appeal, PharmaStem refers to two pieces of scientific evidence introduced at trial that PharmaStem contends support its claim of infringement of the '681 patent. The first is a paper published in 2001 in the New England Journal of Medicine regarding the use of umbilical cord blood in adult transplantations. That paper was cited in promotional materials of CBR and CorCell. Although the paper showed that cord blood could have restorative effects for adults, it did not disclose whether any or all of the trans-plantations consisted of only a single cord blood unit. The paper therefore did nothing to prove how often a single cord blood unit from a single infant is sufficient for adult reconstitution. For that reason, the 2001 paper provided no evidentiary basis from which to infer that the particular cord blood samples preserved by any of the defendants contained a sufficient quantity of stem cells for adult reconstitution.

A second piece of scientific evidence featured by PharmaStem is a 2003 publication by the federal Food and Drug Administration reporting that an advisory committee studying cord blood transplan-tations had recommended that physicians be permitted to conduct adult transplanta-tions “as long as the stem cell dose is adequate.” That evidence is likewise not probative of infringement because the report makes no reference to whether a single unit of cord blood would be used in such transplantations. In fact, the transplant physician who made the presentation that led to the advisory committee’s recommendation explained at trial that his recommendation against limiting transplants by age was “[bjecause we could do cord blood transplants using two cord blood transplant [units].”

Thus, neither of the scientific exhibits cited by PharmaStem addresses whether a single cord blood unit from a single infant is sufficient to reconstitute an adult’s he-matopoietic system. Moreover, and significantly, neither addresses the critical question whether the particular samples preserved by the defendants contained sufficient stem cells for that purpose. Those two pieces of scientific evidence therefore do not overcome the problem with PharmaStem’s evidence that the district court pointed out — that while Phar-maStem may have demonstrated that the preserved cord blood units had significant therapeutic uses, and while cord blood in some amounts could be used to treat adults, the evidence was not sufficient to show that the particular cord blood units stored by the defendants contained sufficient numbers of stem cells to reconstitute the hematopoietic system of a human adult.

D

PharmaStem’s failure to establish that any of the preserved cord blood samples contained sufficient stem cells to reconstitute an adult was not merely a technical flaw in its proof. The evidence at trial showed that the great majority of cord blood transplantations between the first successful transplantation in 1988 and the time of trial had been in children. Indeed, it was not until 1995 that a cord blood transplant was even attempted in an adult. The evidence also showed that more than a single unit of cord blood was used for most cord blood transplants performed on adults; the single unit collected at an individual’s birth was frequently regarded as insufficient to effect hematopoietic reconstitution of an adult.

In support of its infringement claim, PharmaStem points out that each of the defendants provided a small number of cord blood units to transplant physicians for use in transplantation procedures. The evidence shows that the four defendants had provided a total of 33 units of cord blood to transplanters by the time of trial. For the most part, however, that evidence did not distinguish between transplantations of children and transplan-tations of adults. To the extent that the evidence distinguished between the two, it showed that most of the supplied samples were used for transplantations of children. Moreover, with respect to the adult trans-plantations, PharmaStem has not pointed to any evidence that even a single transplanted cord blood unit from one of the defendants resulted in the successful reconstitution of the hematopoietic system of an adult. Thus, the evidence regarding the transplants generally, and the defendants’ experience with transplants in particular, provides no basis from which to infer that some or all of the cord blood units preserved by the defendants must have contained a sufficient number of stem cells for adult reconstitution. For that reason, the district court was correct to hold that the evidence was insufficient to support the jury’s verdict of infringement of the '681 patent.

Contrary to PharmaStem’s contention, the district court’s ruling did not convert a determination as to damages into a ruling on liability. Because of the manner in which PharmaStem sought to prove infringement, it committed itself to a course that had “all-or-nothing” consequences. The district court was correct to conclude that, having chosen not to try to prove that particular cord blood samples or categories of samples contained sufficient stem cells to effect hematopoietic reconstitution of an adult, PharmaStem took the risk that the court would conclude that it had failed to prove that any of the defendants’ cryopre-served samples infringed. The district court’s narrow disposition of the JMOL issue simply held PharmaStem to the consequences of the strategy it adopted at trial.

E

In reaching this conclusion, we reject PharmaStem’s contention that the district court abused its discretion when it determined, following the trial, that the infringement opinion of PharmaStem’s expert witness Dr. Hendrix should have been struck. The district court found her testimony unhelpful to the jury, and not an appropriate subject for expert evidence, because it consisted almost entirely of her quoting from the promotional information and other materials in which the defendants described their business operations for potential customers and investors, and drawing inferences from those materials. The district court did not abuse its discretion in concluding that the jury was fully capable of understanding those materials without expert assistance and that Dr. Hendrix’s testimony should have been excluded. See General Electric Co. v. Joiner, 522 U.S. 136, 141, 118 S.Ct. 512, 139 L.Ed.2d 508 (1997) (abuse of discretion standard applies to district court’s decision to exclude expert testimony).

Dr. Hendrix concluded from those materials that the defendants had in effect admitted that all of the cord blood samples that the defendants preserved contained a sufficient quantity of stem cells to reconstitute an adult. In particular, Dr. Hendrix interpreted the defendants’ statements about their processes for preserving cord blood samples to mean that each of them tested the samples “to determine if there is a sufficient amount of cells for reconstitution for an adult. And then after that time, they cryopreserve it for storage.” She admitted that she did not examine the data obtained by the defendants from their testing of the samples; that she did not know how many, if any, successful adult transplantations had been done with cord blood samples preserved by any of the defendants; and that she did not know whether, when the defendants tested the samples, they determined whether the samples were “sufficient for an adult or sufficient for a child or sufficient for any purpose.” In sum, Dr. Hendrix admitted that a particular company’s decision to store a particular sample did not necessarily mean the sample was sufficient to reconstitute an adult. Nonetheless, she maintained that “[i]f the cord bloods are being stored, and the companies promise that — I mean they state in their websites that there are sufficient cells that they make available for transplantation, pediatric, sibling, older and adults, then I believe that there is the potential in all of those samples that are stored in frozen sanctuary to provide that service.”

There are two problems with Dr. Hendrix’s testimony, as the district court pointed out. First, because her testimony was almost entirely based on an interpretation of the defendants’ marketing materials and materials directed to investors, any expertise on Dr. Hendrix’s part as a cell biologist was of no apparent help to the jury. Whether or not the materials constituted admissions by the defendants that some or all of the preserved samples contained enough stem cells to reconstitute an adult was not a matter as to which Dr. Hendrix’s expertise was of any apparent use. See Daubert v. Merrell Dow Pharms., Inc., 509 U.S. 579, 592, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993) (admission of expert testimony “is premised on an assumption that the expert’s opinion will have a reliable basis in the knowledge and experience of his discipline”). Second, not only was her expertise not necessary or useful to interpret the defendants’ materials, but her interpretation was not a reasonable one. Nowhere did the defendants represent that any of the preserved cord blood samples (much less all of them) contained a sufficient number of stem cells to reconstitute an adult. The representations that the cord blood was of potential use not only for infants and children but also for adults falls significantly short of a representation that the individual cryopre-served cord blood samples each contained enough stem cells to reconstitute an adult.

To be sure, Dr. Hendrix stated in con-clusory terms that she relied for her opinion not only on the defendants’ materials, but also on scientific literature, testimony of experts, and the depositions of representatives of the defendants. She made clear, however, that her opinion was based principally on the assertions by the defendants that the preserved cord blood had potential uses for adults as well as for children. Moreover, Dr. Hendrix did not explain how her reliance on any of the other sources of information supported her inference about whether the defendants’ preserved samples contained an infringing quantity of stem cells.

In short, we agree with the trial court that the defendants’ materials did not constitute sufficient proof of infringement of the '681 patent and that those materials did not become proof of infringement when Dr. Hendrix read those materials back to the jury from the witness stand. There was therefore nothing in Dr. Hendrix’s testimony that sufficed to remedy the insufficiency that the district court pointed out in PharmaStem’s other evidence of infringement of the '681 patent.

IV

With respect to infringement of the '553 patent, the issue presented to us is again a narrow one. There is no dispute that in the 33 instances in which the defendants’ cord blood samples were used in transplant procedures, samples of cord blood containing stem cells were collected, cryopreserved, thawed, and introduced into the patient’s body. In no case, however, were all those steps performed by the same party. Instead, the defendants were typically responsible for collecting and cryopreserving the cord blood samples, while transplant physicians unrelated to the defendants thawed the cord blood and used it for transplanting.

In light of the fact that the defendants did not perform all the steps of the patented method, PharmaStem based its claim of infringement of the '553 patent on the theory of contributory infringement. The district court instructed the jury on contributory infringement and gave the jury special verdict questions that directed the jury’s inquiry to the requirements of that theory.

The court instructed the jury that in order to prove contributory infringement, PharmaStem was required to prove, inter alia, (1) that the defendants “sold or offered to sell cryopreserved cord blood to a transplanter” and (2) that the cryopre-served cord blood that was “sold or offered for sale by the defendant was used by a single entity, or alternatively, by a group of entities that are acting in concert or working together to complete the process of infringement.” The pertinent special verdict questions corresponding to those instructions required the jury to find that “the defendants and the transplant physicians are acting in concert or working together to complete the process of infringement” of the asserted claims of the '553 patent (special verdict question 4) and that the defendants “contributorily infringed the '553 patent by selling or offering to sell cryopreserved cord blood that was actually used by a third party in the direct infringement” of any of the asserted claims (special verdict question 5).

PharmaStem’s theory of contributory infringement was based on the contributory infringement section of the Patent Act, 35 U.S.C. § 271(c), which provides: “Whoever offers to sell or sells ... a component of a patented machine, manufacture, combination or composition,- or a material or apparatus for use in practicing a patented process, constituting a material part of the invention, knowing the same to be especially made or especially adapted for use in an infringement of such patent” shall be liable as a contributory infringer. The jury found in PharmaStem’s favor on each of the special verdict questions pertaining to contributory infringement and accordingly returned a verdict of liability against all of the defendants on the '553 patent.

The issue on appeal is whether there was substantial evidence to support the jury’s finding, in response to special verdict question 5, that each of the defendants “contributorily infringed the '553 patent by selling or offering to sell cryopreserved cord blood that was actually used by a third party in ... direct infringement” of that patent. The district court ruled that the evidence was sufficient to show that the defendants sold a service to families of newborn infants (collection, processing, and eryopreservation of the newborn’s umbilical cord blood), but not to show that they sold the cord blood units themselves, which belonged to the families throughout, and certainly not to show that the defendants sold the cord blood units to the transplanters.

The district court construed the contributory infringement statute to require a sale or an offer of sale of a product; the statute is not satisfied, the court ruled, by the provision of a service for compensation. Because liability under section 271(c) “is clearly dependent upon the accused infringer’s selling or offering to sell a component of the patented process, here cord blood units,” the court held that the jury’s verdict on contributory infringement could not stand, and it therefore granted the defendants’ JMOL motions with respect to the '553 patent.

In challenging the district court’s ruling, PharmaStem first argues that the jury could properly characterize as a “sale” the transaction in which the defendants obtained unprocessed umbilical cord blood, converted it into a therapeutically useful, cryopreserved cord blood product, and later provided it to transplant physicians at the behest of the client family. While cord blood is certainly a product, the transaction between the defendants and their clients is plainly not the sale of “a material or apparatus for use in practicing a patented process,” as is required by section 271(c) with respect to method patents. The evidence at trial showed that the cord blood remained the property of the families throughout the period in which the defendants stored it. The defendants were never owners of the blood, but instead were merely bailees; they were not free to dispose of the blood as they chose, but were contractually obligated to preserve it pending the families’ need for it at some point in the future. On those occasions when the cord blood was needed, the defendants provided the blood to tran-splanters in satisfaction of their contractual obligation to ship the families’ cord blood samples to a transplanter upon direction. Neither that transaction nor any earlier transaction between the families and the defendants constituted a “sale” of the cord blood. See Sturm v. Boker, 150 U.S. 312, 329-30, 14 S.Ct. 99, 37 L.Ed. 1093 (1893) (“The recognized distinction between bailment and sale is that, when the identical article is to be returned in the same or in some altered form, the contract is one of bailment, and the title to the property is not changed. On the other hand, when there is no obligation to return the specific article, and the receiver is at liberty to return another thing of value, he becomes a debtor to make the return, and the title to the property is changed.”). Rather, as the trial court held, the transaction between the families and the defendants constituted the provision of a service for a fee.

In the alternative, PharmaStem argues that even if the district court was correct to characterize the defendants’ activities as providing a service rather than selling a product, the court still should have upheld the jury’s verdict of contributory infringement. In this regard, Phar-maStem argues that section 271(c) is not limited to the sale of a product, but extends to the sale of a service.

PharmaStem’s argument is contrary to both the language and the legislative history of section 271(c). The statute provides, in pertinent part, that a contributory in-fringer is one who “offers to sell or sells within the United States a patented machine, manufacture, combination or composition, or a material or apparatus for use in practicing a patented process.” Although that language describes in various different ways the items that may be sold for purposes of creating liability for contributory infringement, all of the descriptions refer to the sale of a product of some sort; none of them refer to the provision of a service. Under the plain language of the statute, a person who provides a service that assists another in committing patent infringement may be subject to liability under section 271(b) for active inducement of infringement, but not under section 271(c) for contributory infringement.

The legislative background of section 271(c) makes clear that the district court was correct to construe that statute as confined to its plain terms. Prior to the 1952 Patent Act, no statute defined contributory infringement. Instead, as a result of court decisions, infringement was divided into two categories: “direct infringement,” which was the unauthorized making, using, or selling of the patented invention, and “contributory infringement,” which was “any other activity where, although not technically making, using, or selling, the defendant displayed sufficient culpability to be held liable as an infringer.” Hewlett-Packard Co. v. Bausch & Lomb Inc., 909 F.2d 1464, 1469 (Fed.Cir.1990). The 1952 Act did not make a substantive change in the law of contributory infringement, but it divided the judicially created category of contributory infringement into two statutory subsections, section 271(b) (inducement of infringement) and section 271(c) (contributory infringement). The most common type of pre-1952 contributory infringement cases were those in which “a seller would sell a component that was not covered by the claims of a patent but which had no other use except the claimed product or process.” Id. That form of contributory infringement was codified in section 271(c). Id.

The Senate Report on the 1952 Act confirms that section 271(c) was intended to deal with a particular subset of what had previously been considered contributory infringement, consisting of cases in which a party sells a particular component that is known to be intended for an infringing use and is useful only for infringement. The Senate Report states that section 271(b) recites “in broad terms that one who aids and abets an infringement is likewise an infringer” whereas section 271(c) deals specifically with the most common form of contributory infringement and “is much more restricted than many proponents of contributory infringement believe should be the case.” S.Rep. No. 89-1959, at 8, 28 (1952) (characterizing section 271(c) as applying to “one who sells a component part of a patented invention or material or apparatus for use therein”), reprinted in 1952 U.S.C.C.A.N. 2394, 2402, 2421; see also Jones v. Radio Corp. of Am., 131 F.Supp. 82, 83 (S.D.N.Y.1955) (in light of legislative history of 1952 Act, section 271(c) does not apply if the defendant did not sell a component of the patented combination).

In summary, the district court correctly concluded that the defendants did not sell a product and that what they provided to customers was a service for compensation. The evidence showed that the cord blood the defendants collected and preserved was never their property; instead, it remained the property of the families who engaged their services. The defendants were never the owners of the blood and thus never “sold” the blood to the families when it was needed. The district court therefore properly held that the defendants could not be found liable for contributory infringement under section 271(c).

There is another reason why the jury’s verdict in this case cannot stand. The court instructed the jury, without objection from PharmaStem, that it was necessary for the sale in question to be made “to a transplanter.” Yet even if a sale of a service were deemed sufficient to constitute a “sale” for purposes of section 271(c), there was no evidence that any of the defendants made a sale of either products or services to the transplanters. To the contrary, the evidence showed that the service the defendants provided was a service to the donor families, for which the families paid a fee, and that there was no sale of any sort by the defendants to the transplanters or any fee paid by the tran-splanters to the defendants. The defendants simply transferred the cord blood units to designated transplanters upon direction from the families. Such a transaction does not constitute a “sale” to a tran-splanter under any definition of the term “sale.” Accordingly, the district court properly concluded that the jury’s verdict was legally insufficient to establish infringement under the law of the case as given by the court to the jury and accepted by the parties. We therefore uphold the portion of the court’s judgment granting the defendants’ JMOL motions with respect to the '553 patent.

V

The jury returned verdicts in favor of PharmaStem on the defendants’ counterclaims challenging the validity of the two patents in suit. In its opinion on the defendants’ JMOL motions, the district court held that the jury’s verdicts on the validity issues were supported by substantial evidence. In their cross-appeal, the defendants contest the portions of the trial court’s judgment rejecting their challenges to the patents on grounds of anticipation, obviousness, and (in the case of the '681 patent) indefiniteness. Each of those issues presents a close question. Because we hold that the district court should have granted the defendants’ motion for JMOL on the issue of obviousness, it is not necessary for us to address the defendants’ arguments with respect to the issues of indefiniteness and anticipation.

A

Obviousness is a legal conclusion that we review de novo. The statutory standard requires us to decide whether the subject matter of the claimed invention “would have been obvious at the time the invention was made to a person of ordinary skill in the art to which [the subject matter of the invention] pertains.” 35 U.S.C. § 103(a); Eli Lilly & Co. v. Zenith Goldline Pharms., Inc., 471 F.3d 1369, 1377 (Fed.Cir.2006); DyStar Textilfarben GmbH & Co. Deutschland KG v. C.H. Patrick Co., 464 F.3d 1356, 1360 (Fed.Cir.2006). Underpinning that legal issue are factual questions relating to the scope and content of the prior art, the differences between the prior art and the claimed invention, the level of ordinary skill in the art, and any relevant secondary considerations, such as commercial success, long-felt need, and the failure of others. See Eli Lilly, 471 F.3d at 1377; DyStar, 464 F.3d at 1360; Medichem, S.A. v. Rolabo, S.L., 437 F.3d 1157, 1164 (Fed.Cir.2006). Under Third Circuit law, which in this case dictates the standard for reviewing the denial of the motion for JMOL, we review the district court’s action “de novo by reapplying the JMOL standard” applied by the district court. Seachange Int’l, Inc. v. C-COR Inc., 413 F.3d 1361, 1368 (Fed.Cir.2005). Thus, in reviewing the denial of the JMOL motion on the issue of obviousness, we examine the evidence in the light most favorable to the verdict and determine whether a reasonable jury could have found all the facts necessary to support the verdict of nonobviousness, i.e., whether substantial evidence supports the verdict. See Caver v. City of Trenton, 420 F.3d 243, 262 (3d Cir.2005); Connell v. Sears, Roebuck & Co., 722 F.2d 1542, 1546 (Fed.Cir.1983).

B

The defendants contend that the two patents in suit are invalid for obviousness based on a combination of several prior art references. In such a case, the burden falls on the patent challenger to show by clear and convincing evidence that a person of ordinary skill in the art would have had reason to attempt to make the composition or device, or carry out the claimed process, and would have had a reasonable expectation of success in doing so. See Medichem, 437 F.3d at 1164; Noelle v. Lederman, 355 F.3d 1343, 1351-52 (Fed.Cir.2004); Brown & Williamson Tobacco Corp. v. Philip Morris, Inc., 229 F.3d 1120, 1121 (Fed.Cir.2000); see also KSR Int’l Co. v. Teleflex Inc., — U.S. -, 127 S.Ct. 1727, 1740, 167 L.Ed.2d 705 (2007) (a combination of elements “must do more than yield a predictable result”; combining elements that work together “in an unexpected and fruitful manner” would not have been obvious).

In view of the prior art references, the first part of that test is plainly satisfied here. The idea of using cryopreserved cord blood to effect hematopoietic reconstitution was not new at the time the inventors filed the applications that matured into the '681 and '553 patents. Two of the prior art references — articles by Ende and Knudtzon — suggest using cord blood for that purpose. Two others — an article by Koike and a doctoral dissertation by Vidal — suggest eryopreservation and storage of the cord blood until needed. Accordingly, this is not a case in which there is any serious question whether there was a suggestion or motivation to devise the patented composition or process.

The more difficult question is whether the prior art would have given rise to a reasonable expectation of success in creating the process claimed in the '553 patent and the composition claimed in the '681 patent. In addressing that question, the parties focus on whether the inventors had a reasonable expectation that cord blood could be successfully used in transplants for hematopoietic reconstitution.

On the question whether the inventors had a reasonable expectation of success, the district court relied principally on testimony by PharmaStem’s expert, Dr. Irwin Bernstein. In testimony cited by the court, Dr. Bernstein explained that there were problems with transplant tissues that had been used previously, including bone marrow and adult blood; that those working in the transplant field did not believe blood would be suitable as a transplant tissue; and that researchers in his group were surprised at the successful result of the first transplant of cord blood into a human. That evidence, according to the court, justified the jury in finding that persons of skill in the field of hematopoietic reconstitution “would not have expected cord blood to be a successful transplant tissue.” In light of that evidence and the evidence of secondary considerations such as long-felt need and commercial success, and in light of the PTO’s issuance of the patents over several of the prior art references that were in issue at trial, the court concluded that “there is no basis to overturn the jury’s verdict that the Patents-In-Suit are not obvious.”

The defendants argue that the prior art suggested using cryopreserved cord blood for hematopoietic reconstitution and showed that persons of skill in the field would have had a reasonable expectation that the use of cord blood in transplants would be successful. For that reason, according to the defendants, the asserted claims were obvious as a matter of law.

Like the district court, PharmaStem relies principally on Dr. Bernstein’s testimony to support its argument that the asserted claims of the ’681 and '553 patents were not invalid for obviousness. Citing his testimony, PharmaStem argues that those skilled in the art at the time of the inventions “did not even yet know of the presence of stem cells in cord blood.” PharmaStem argues that Dr. Bernstein’s assertion that it was not known that cord blood contained stem cells, combined with his testimony regarding problems with transplant tissues used prior to the '681 and '553 patents, shows that those in the field of hematopoietic reconstitution “would not have expected cord blood to be a successful transplant tissue.”

The cornerstone of Dr. Bernstein’s testimony at trial was that none of the prior art showed that cord blood contains stem cells. According to Dr. Bernstein, the presence of stem cells in cord blood was not conclusively established before the mouse studies described in the joint specification and the 1988 human cord blood transplant referred to in the specification of the '553 patent.

The problem with Dr. Bernstein’s testimony about the prior art references is that it cannot be reconciled with statements made by the inventors in the joint specification and with the prior art references themselves. Dr. Bernstein distinguished each of the prior art references on the ground that none of them disclosed the presence of stem cells in cord blood. Even though some of the references referred to stem cells as being present in cord blood, Dr. Bernstein took the position that those statements in the prior art references reflected flawed nomenclature and that the most the data underlying the prior art references showed was that cord blood contained progenitor cells. Progenitor cells are the cells that generate several different types of cells that make up the blood and immune system but are less primitive than hematopoietic stem cells. According to Dr. Bernstein, it was not proved that stem cells, as opposed to the less primitive progenitor cells, are present in cord blood until the patentees performed the mouse experiments reported in the joint specification. Those experiments showed that relatively small amounts of fetal blood were sufficient to effect hema-topoietic reconstitution in lethally irradiated mice. Dr. Bernstein added that in light of the poor results obtained with trans-plantations of adult blood “it had to take a leap of thinking that cord blood was different.”

The joint specification, however, tells a different story. There, the inventors acknowledged that it was previously known that the properties of cord blood are quite different from those of adult blood and that hematopoietic stem cells had been found in cord blood in much greater concentrations than in adult blood. Citing a number of references, the inventors stated the following:

A human hematopoietic colony-forming cell with the ability to generate progenitors for secondary colonies has been identified in human umbilical cord blood. In addition, hematopoietic stem cells have been demonstrated in human umbilical cord blood, by colony formation, to occur at a much higher level than that found in the adult. The presence of circulating hematopoietic progenitor cells in human fetal blood has also been shown. Human fetal and neonatal blood has been reported to contain megaka-ryocyte and burst erythroblast progenitors with increased numbers of eryth-roid progenitors in human cord blood or fetal liver relative to adult blood.

'681 patent, col. 4,11. 15-34 (citations omitted); '553 patent, col. 4,11. 21-42 (citations omitted).

That excerpt from the specification cannot be squared with Dr. Bernstein’s characterization of the prior art. Contrary to Dr. Bernstein’s contention that the prior art did not disclose the presence of stem cells in cord blood, the inventors cited several prior art references and stated flatly that “hematopoietic stem cells have been demonstrated in human umbilical cord blood.” Moreover, the inventors noted that the prior art references showed that the concentration of stem cells in cord blood was “at a much higher level than in the adult.” Nor can those statements in the specification be dismissed as reflecting a careless use of the term “hematopoietic stem cell,” i.e., the use of that term when the inventors meant to refer to progenitor cells. That is made clear by context, as the sentence that immediately follows the reference to “hematopoietic stem cells” states that “the presence of hematopoietic progenitor cells in human fetal blood has also been shown.”

Accordingly, PharmaStem’s argument that stem cells had not been proved to exist in cord blood prior to the experiments described in the patents is contrary to the representation in the specification that the prior art disclosed stem cells in cord blood. Admissions in the specification regarding the prior art are binding on the patentee for purposes of a later inquiry into obviousness. See Constant v. Advanced Micro-Devices, Inc., 848 F.2d 1560, 1570 (Fed.Cir.1988) (“A statement in the patent that something is in the prior art is binding on the applicant and patentee for determinations of anticipation and obviousness.”); Sjolund v. Musland, 847 F.2d 1573, 1577-79 (Fed.Cir.1988) (patent specification admitted that certain matter was prior art, and thus “the jury was not free to disregard [that matter]” and “must have accepted [it] as prior art, as a matter of law”); In re Font, 675 F.2d 297, 300 (CCPA 1982); In re Nomiya, 509 F.2d 566, 571 (CCPA 1975).

Nor is there any unfairness in holding the inventors to the consequences of their admissions, as their characterization of the prior art as showing the presence of stem cells in cord blood is hardly unreasonable. At trial, the defendants’ expert acknowledged that, prior to the time of the first successful cord blood transplant, stem cells could not be conclusively proved to be present in cord blood. He explained, however, that in light of the discovery of substantial numbers of progenitor cells in cord blood — roughly equivalent to the number of such cells in bone marrow — it was appropriate for the authors of the prior art references to infer the presence of stem cells in cord blood, even though positive proof of their presence was not available.

The prior art references provide strong support for that interpretation. Mouse studies reported by Barnes in a 1964 article showed that the blood of fetal and neonatal mice contained a much greater concentration of colony-forming units (i.e., progenitor cells) than adult blood. Barnes identified the colonies in question as containing stem cells. A 1974 article by Knudtzon similarly noted that an “increased concentration of hemopoietic stem cells has been found in the blood of mouse embryos when compared to the concentration after birth.” Knudtzon also conducted tests on human umbilical cord blood, determining that the concentration of in vitro colony-forming cells in cord blood is likewise much greater than in human adult blood and that the concentration is comparable to the concentration in bone marrow tissue. Knudtzon concluded that “the finding of an increased concentration of colony-forming cells in human cord blood comparable in number with human bone marrow cultures indicates that cord blood might be used as a source of hemopoietic stem cells for the restoration of bone marrow function in humans.” Two years later, a case study by Ende reported a transfusion of 45 milliliters of human cord blood into a human patient, which resulted in a temporary hematopoietic graft that lasted for five weeks. Ende cited other research indicating that a similar or even larger amount of bone marrow would be needed to achieve a successful permanent graft.

A 1978 article by Prindull noted that animal experiments showed that fetal blood contains more than 100 times as many stem cells as are present in adult blood and suggested that because the fetal hematopoietic system is in a state of physiologic proliferation, human cord blood could constitute a source of hematopoietic stem cells. An article by Koike, in 1982, described the results of freezing and thawing cells derived from bone marrow and cord blood. It showed that even immature progenitor cells can survive cryopreservation and concluded that because cord blood contains “many pluripotent and nearby progenitor cells comparable to marrow cells,” cord blood or other fetal tissue could be a useful source of hematopoietic progenitor cells for transplantation. In 1985, a doctoral dissertation by Vidal concluded, based on various studies, that “cord blood contains sufficient hemato-poietic stem cells to effect a transplant,” that “cord blood can be used for this purpose,” and that “eryopreserved cord blood banks might exist.”

That collection of prior art shows (1) that bone marrow transplants can result in hematopoietic reconstitution; (2) that cord blood, like bone marrow but unlike adult blood, contains large numbers of progenitor cells; and (3) that the high concentration of primitive progenitor cells in cord blood suggests that in humans, as in mice, the cells responsible for hematopoiesis migrate at about the time of birth from fetal organs to the bone marrow. Under those circumstances, it was reasonable for the inventors of the patent, like the authors of the prior art references, to infer the presence of high concentrations of stem cells in cord blood, even though the prior art studies did not offer conclusive proof of their presence.

C

Given that the jury was legally required to find that those of skill in the art would believe that cord blood contained hematopoietic stem cells, the question before us is whether a reasonable jury could nonetheless have found the invention non-obvious. We conclude a reasonable jury could not have done so. While the inventors may have proved conclusively what was strongly suspected before — that umbilical cord blood is capable of hemato-poietic reconstitution — and while their work may have significantly advanced the state of the science of hematopoietic trans-plantations by eliminating any doubt as to the presence of stem cells in cord blood, the mouse experiments and the conclusions drawn from them were not inventive in nature. Instead, the inventors merely used routine research methods to prove what was already believed to be the case. Scientific confirmation of what was already believed to be true may be a valuable contribution, but it does not give rise to a patentable invention. See KSR, 127 S.Ct. at 1732 (“Granting patent protection to advances that would occur in the ordinary course without real innovation retards progress_”); Pfizer, Inc. v. Apotex, Inc., 480 F.3d 1348, 1367-69 (Fed.Cir.2007) (simply because the formation and properties of a new compound must be verified through testing does not mean that the compound satisfies the test for patentability “since the expectation of success need only be reasonable, not absolute”); In re Merck & Co., 800 F.2d 1091, 1097 (Fed.Cir.1986) (“Obviousness does not require absolute predictability”). Good science and useful contributions do not necessarily result in patentability.

This court’s decision in In re O’Farrell, 853 F.2d 894, 903 (Fed.Cir.1988), provides useful guidance for determining whether the expectation of success from a particular line of inquiry is great enough to render a resulting invention obvious. The court noted that obviousness “does not require absolute predictability of success. Indeed, for many inventions that seem quite obvious, there is no absolute predictability of success until the invention is reduced to practice.” 853 F.2d at 903. On the other hand, the court explained, an invention would not be invalid for obviousness if the inventor would have been motivated “to vary all parameters or try each of numerous possible choices until one possibly arrived at a successful result, where the prior art gave either no indication of which parameters were critical or no direction as to which of many possible choices is likely to be successful.” Id. Likewise, an invention would not be deemed obvious if all that was suggested “was to explore a new technology or general approach that seemed to be a promising field of experimentation, where the prior art gave only general guidance as to the particular form of the claimed invention or how to achieve it.” Id.; see also Medichem, S.A. v. Rolabo, S.L., 437 F.3d 1157, 1166-67 (Fed.Cir.2006).

This case is not one in which “the prior art gave either no indication of which parameters were critical or no direction as to which of many possible choices is likely to be successful,” nor is it one in which the prior art “gave only general guidance as to the particular form of the invention or how to achieve it.” O’Farrell, 853 F.2d at 903. The prior art suggested cryopre-serving cord blood from a single infant and transplanting that blood into a patient to achieve hematopoietic reconstitution. PharmaStem does not suggest, and Dr. Bernstein’s testimony did not reveal, that there was an array of possible choices as to how to achieve that objective or that there were problems to be solved in implementing the prior art suggestion that were not adumbrated in the prior art. To the contrary, the joint specification indicates that each step of the cryopreservation and transplantation procedure had been spelled out in the prior art. Phar-maStem does not claim that there was anything novel about the method by which it proposed to collect, cryopreserve, and transplant the cord blood. Instead, in responding to the defendants’ obviousness challenge, PharmaStem focuses entirely on the purported novelty of its proof that stem cells are present in fetal blood, a demonstration that Dr. Bernstein testified was necessary to give transplant physicians sufficient confidence in the use of cord blood for hematopoietic reconstitution to try the procedure on humans. As we have explained, however, providing proof sufficient to justify conducting in vivo procedures on humans, while useful, is not a test of patentability. The evidence at trial demonstrated that the patentees did not invent a new procedure or a new composition; instead, they simply provided experimental proof that the cord blood could be used to effect hematopoietic reconstitution of mice and, by extrapolation, could be expected to work in humans as well.

D

In addition to its reliance on Dr. Bernstein’s testimony about the prior art references, PharmaStem invokes various secondary considerations that it contends support the jury’s verdict on obviousness. In particular, PharmaStem points to evidence that the inventors were widely recognized as pioneers in the use of cord blood for hematopoietic reconstitution, including statements by the defendants and their representatives. Defendant Via-Cord’s business plan praised the inventors as “trailblazers,” and a founder of defendant Cryo-Cell wrote to the inventors’ company and stated: “[N]o one will ever dispute that you, as the pioneers in the medical technology ... will be the frontrunners in the field of utilizing the blood from the umbilical cord for restoring he-matopoietic [sic] through marrow transplants.” Even the defendants’ expert had previously referred to the inventors as the first to suggest the use of human umbilical cord blood as a source of transplantable hematopoietic stem cells, although he disclaimed those statements at trial on the ground that he had subsequently determined that it was incorrect to give the inventors credit for conceiving the invention. The problem with that evidence is that there was no indication that the praise for the inventors’ work was based on any inventive contribution they made, as opposed to their proof, through laboratory work, that fetal blood contains large numbers of stem cells. As noted, the former is a basis for patentability; the latter is not.

PharmaStem also points to Dr. Bernstein’s testimony that researchers in his group in Seattle were “surprised” at the successful human cord blood transplantation in 1988. There are two problems with that evidence. First, there was no indication that either Dr. Bernstein or members of his research group were previously aware of the prior art references that laid the groundwork for the inventors’ experiments. Dr. Bernstein stated that his surprise at the successful use of cord blood was based on the poor results obtained with transplants of adult blood; he did not state that the success of the human transplant would have been surprising to one familiar with the prior art references introduced at trial, including those references that featured the important differences between adult blood and cord blood as potential transplant tissues.

Second, Dr. Bernstein tied the “surprise” of his research group to the success of the 1988 human cord blood transplant, not to the results reported in the patents. Although the transplant was based on work done by the inventors, it took place long after the filing of the application for the '681 patent and shortly before the filing of the application for the '553 patent. As a result, the specification of the '681 patent does not refer to the 1988 transplant at all, and the specification of the '553 patent does not contain any account of the results of that transplant. At the time of the application for the '553 patent, all that was known and disclosed about the 1988 transplant was that it had been attempted.

Moreover, although it is true, as Phar-maStem argued, that physicians began performing human transplants only after the inventors conducted their mouse experiments, the evidence at trial showed that physicians were reluctant to try a new procedure such as a cord blood transplant on humans without a very strong scientific basis for concluding that it was likely to work. The prior art already indicated that cord blood was likely to be a valuable source of hematopoietic stem cells; the mouse studies merely provided supporting evidence for that conclusion, evidence that the transplant physicians regarded as sufficient to justify trying the procedure on a human child.

E

Finally, PharmaStem argues that the jury’s verdict is supported by the decision of the Patent and Trademark Office (“PTO”) to issue the '681 and '553 patents, and to confirm the '681 patent following reexamination, over some of the same references that the defendants cited at trial. When the party asserting invalidity relies on references that were considered during examination or reexamination, that party “bears the added burden of overcoming the deference that is due to a qualified government agency presumed to have done its job.” Polaroid Corp. v. Eastman Kodak Co., 789 F.2d 1556, 1560 (Fed.Cir.1986); see also Al-Site Corp. v. VSI Int’l, Inc., 174 F.3d 1308, 1323 (Fed.Cir.1999).

The examiner who issued the reexamination certificate for the '681 patent summarized her analysis of the prior art by stating that none of the cited references “addresses the presence of hematopoietic stem cells in umbilical cord or placental blood, that these cells may successfully be cryopreserved, or that, as a collection from a single human at birth, these cells may comprise an amount that is sufficient to effect hematopoietic reconstitution of a human adult.” That explanation is flawed for three reasons. First, as we have explained, the prior art references and the admissions in the specification address the presence of hematopoietic stem cells in cord blood, even though the references may not conclusively prove their presence. Second, Koike established that cord blood could be cryopreserved without substantial losses in the population of progenitor cells; the inventors contributed nothing more with respect to cryopreservation, as them mouse experiments were not performed with cryopreserved blood. Third, while the joint specification states that the amount of cord blood obtained at the time of birth would often be sufficient to transplant an adult, the inventors reached that conclusion simply by comparing the known properties of bone marrow against the results of routine testing of their own cord blood samples.

The specification explains that, because of the inability to determine the number of stem cells present in a particular composition, researchers and transplanters use surrogate assays from which they can infer that stem cells are present and in roughly what numbers. One of the surrogate assays that the joint specification describes in detail and that was the subject of testimony at trial is the assay for CFU-GM (colony-forming units for granulyte and macrophage cells), i.e., progenitor cells that produce the more specialized granu-lyte and macrophage cells. The inventors compared the results of conventional CFU-GM assays of cord blood samples with published reports of the number of CFU-GM in bone marrow samples sufficient for successful hematopoietic reconstitution. '681 patent, col. 50, line 64, to col. 51, line 15; '553 patent, col. 51, 11. 44-68. Thus, the inventors reported that prior art studies showed that in cases involving au-tologous bone marrow transplants, “rapid repopulation of hematopoiesis in patients with acute leukemia was associated with as few as 0.25 million progenitor cells [CFU-GM].” '681 patent, col. 13, 11. 49-54. The inventors’ assays of cord blood samples, confirmed by prior art studies, showed that 50 milliliters of cord blood would contain up to more than 0.5 million CFU-GM. Id., col. 13, 11. 55-63. Thus, the inventors’ conclusion that a single unit of cord blood can result in hematopoietic reconstitution of an adult was simply the result of a comparison between the well-known properties of bone marrow and their own conventional assays of a number of samples of cord blood.

In sum, while the issue of obviousness in this case presents us with a difficult question in light of the standards of proof and review that are applied to an appellate challenge to a jury verdict of nonobviousness, we are persuaded that there was clear and convincing evidence that the asserted claims of the '681 and '553 patents would have been obvious and that it was unreasonable for the jury to reach the opposite conclusion. We therefore reverse the denial of JMOL on that issue and remand to the district court for entry of judgment in the defendants’ favor.

VI

This was a closely contested case both at trial and on appeal, and the JMOL motions presented the district court with an unusually difficult set of challenges. We are satisfied that the district court correctly resolved each of the issues that the parties have raised and we have addressed on appeal, with the sole exception of the cross-appeal on the issue of obviousness. We therefore affirm the judgment of the district court with respect to the appeal but reverse the judgment on the cross-appeal with respect to the issue of obviousness. As to that issue, we reverse and remand to the district court for entry of judgment in the defendants’ favor.

Each party shall bear its own costs for this appeal and cross-appeal.

AFFIRMED IN PART, REVERSED IN PART, and REMANDED.

NEWMAN, Circuit Judge,

dissenting.

I respectfully dissent. After a three week trial the jury sustained the validity of these patents, the district court in a thorough opinion upheld the verdicts of validity, and validity was confirmed in three reexaminations by the Patent and Trademark Office. Today my colleagues on this panel hold that the inventions in the '681 patent and its continuation-in-part the '558 patent are obvious to them, and not infringed.

The undisputed evidence at trial was that these long-sought life-saving inventions were achieved amid general scientific skepticism, despite the extensive research that was being conducted by many scientists in this field, as set forth in the patents in suit. The discoveries of these inventors were met with universal acclaim and widespread utilization, including the founding of many commercial enterprises, all of which are reported to have licensed the patents except for these defendants. Unimpressed by these considerations, my colleagues on this panel now reconstruct these inventions by selection and inference, with perfect hindsight of the discoveries. The evidence at trial was that this achievement eluded persons working in the field, despite speculation concerning its potential and recognition of its value if it could actually be achieved; despite the powerful interest in such a life-saving advance. Instead, my colleagues simply reweigh selectively extracted evidence, ignore the actual peer response and acclaim at the time these inventions were made, and decide that this long-sought advance would have been obvious to this court.

Inventors Edward A. Boyse, Hal E. Broxmeyer, and Gordon W. Douglas made possible a new industry with PharmaS-tem’s predecessor Biocyte, Inc., founded by the inventors. The record contains many publications reporting the work of these inventors, and the evidence was undisputed that they were the first to achieve the transplantation of umbilical cord stem cells for reconstitution of the human hema-topoietic system. Although my colleagues manage to reconstruct this extensive scientific effort as simple routine that is obvious to judges, the processes of discovery in complex science make it particularly necessary to view the achievement in the context of the knowledge at the time the invention was made, and to judge it as it was judged by scientific peers at that time, with the assistance of the hard fact of commercial success in a field in which the need was great and success had long been eluded. See Graham v. John Deere Co., 383 U.S. 1, 17-18, 86 S.Ct. 684, 15 L.Ed.2d 545 (1966) (“Such secondary considerations as commercial success, long felt but unsolved needs, failure of others, etc., might be utilized to give light to the circumstances surrounding the origin of the subject matter sought to be patented.”) (quoted in KSR International Co. v. Teleflex Inc., - U.S. -, 127 S.Ct. 1727, 1734, 167 L.Ed.2d 705 (2007)).

The panel majority scours the prior art for clues that could fit the eventual achievement, and then rules that the achievement was obvious, no matter that it eluded the others whose work is now compiled by this court so as to invalidate these patents. The “prior art” selected by my colleagues spans many years of scientific interest and effort, yet the ultimate discovery of the presence of stem cells along with or instead of progenitor cells, the successful preservation of these cells, the extensive experimentation with transplantation into animal models and ultimately into humans, and the successful hemato-poietic reconstitution of blood that has been destroyed by disease or radiation, was not achieved in the prior art. The judicial determination of “obviousness” should be made in the context of the state of knowledge at the time these inventions were made. Nor should the courts lose sight of the powerful policy that underlies the patent law, whereby recognition and protection of technological and scientific advance is legally established in order to serve the public interest in having the benefit of such advance through economic enterprise.

My colleagues ignore not only the scientific experts who testified at the trial, but also the PTO examiners who conducted the three reexaminations. In Dickinson v. Zurko, 527 U.S. 150, 119 S.Ct. 1816, 144 L.Ed.2d 143 (1999) this court was reminded of its obligation to give appropriate deference to agency expertise, including that of the PTO. The references that are analyzed by the panel majority, in its sua sponte finding of obviousness, were before the PTO for examination and multiple reexaminations. My colleagues do not explain where the PTO went wrong; instead, they rearrange the past, criticize the acclaim heaped on these inventors, and propose that if the people in this field knew what this court knows, they would not have been so impressed.

To the contrary: the acclaim sounded by even these defendants is a powerful testament to how this invention was viewed. From my colleagues’ invalidation of these patents on the ground of obviousness, reversing the jury verdict, I respectfully dissent. I must also dissent from the rejection of the jury verdict of infringement, for the district court applied a new and incorrect evidentiary standard that does not warrant ratification.

THE VALIDITY ISSUES

The jury’s special verdicts upholding patent validity were sustained by the district court on post-trial motions. The defendants raised the ever-present multiple grounds of attack that appear in patent cases, and cross-appeal the jury verdicts on the issues of anticipation, indefiniteness, and obviousness, but do not appeal the verdicts for the plaintiff on the issues of inventorship, inequitable conduct, and antitrust violation. My colleagues reverse the jury verdict of unobviousness, and decline to reach the verdicts upholding validity on the issues of anticipation and indefiniteness. The district court sustained each of these verdicts. These issues were also raised for multiple reexaminations, and the PTO upheld patent validity on these grounds.

The teaching of Cardinal Chemical Co. v. Morton International, Inc., 508 U.S. 83, 97, 113 S.Ct. 1967, 124 L.Ed.2d 1 (1993) (“[T]he Federal Circuit is not a court of last resort. If that court had jurisdiction while the case was pending before it, the ease remains alive (barring other changes) when it comes to us. The Federal Circuit’s determination that the patents were not infringed is subject to review in this Court, and if we reverse that determination, we are not prevented from considering the question of validity merely because a lower court thought it superfluous.”), strongly encourages our appellate review of the major issues that were decided and appealed, if such issues would be relevant to patent validity upon further proceedings in the Court. Review of the issues of validity that were litigated sheds further light on the nature of the invention; leaving these issues in silent limbo, despite the elaborate trial and appellate briefing and argument of these issues, distorts the context of the jury verdicts as well as the reexaminations. In this context I discuss the several issues of validity that are appealed, and explain why their judgment also warrants affirmance.

Anticipation

The jury found that the patents had not been proven invalid on the ground of anticipation. “Anticipation” means lack of novelty; that is, that the invention was already known. It is a factual question whose finding, when tried to a jury, is reviewed for support by substantial evidence on the record as a whole. Acromed Corp. v. Sofamor Danek Group, Inc., 253 F.3d 1371, 1378-79 (Fed.Cir.2001); Advanced Display Sys. v. Kent State Univ., 212 F.3d 1272, 1281 (Fed.Cir.2000).

A patent claim is deemed anticipated when every element and limitation of the claim is found in a single prior art reference, either explicitly or inherently. Dayco Products, Inc. v. Total Containment, Inc., 329 F.3d 1358, 1368 (Fed.Cir.2003). In order to anticipate, the reference must place a person who has ordinary skill in the field of the invention, in possession of the invention. See Akzo N.V. v. United States Int’l Trade Comm’n, 808 F.2d 1471, 1479 (Fed.Cir.1986) (“anticipation requires that each and every element of the claimed invention be disclosed in a prior art reference. In addition, the prior art reference must be enabling, thus placing the allegedly disclosed matter in the possession of the public.”)

The reference on which the defendants rely for anticipation is an article by Keni-chi Koike entitled “Cryopreservation of Pluripotent and Committed Hemopoietic Progenitor Cells from Human Bone Marrow and Cord Blood,” 25 Acta Paediatrica Japónica 275 (1983). Koike describes the preservation, by freezing in liquid nitrogen, of pluripotent and progenitor cells of bone marrow and umbilical cord blood, and shows that these cells retain much of their progenitor activity upon thawing. Koike does not mention stem cells, and states that “hematopoietic progenitor cells, especially pluripotent progenitor cells are the most important to repopulate the bone marrow.” Id. at 276. Koike concludes with the suggestion that fetal cells or organs may be a source of progenitor cells for marrow transplantation, in the following statement:

[T]he results that cord blood cells contain many pluripotent and nearby progenitor cells comparable to marrow cells, indicate that fetal hematopoietic cells or organs may be useful as one of the sources of hematopoietic progenitor cells for marrow transplantation.

Koike at 281.

The defendants argued at trial, and repeat on this appeal, that even if stem cells were not known or shown by Koike to be present in umbilical cord blood, the claims are “inherently” anticipated by Koike because stem cells were present even if unknown. PharmaStem responded that inherent anticipation is avoided by lack of recognition, by lack of enablement, and by the limitations in the claims, including for the '681 claims the limitations to therapeutic compositions and the requirements that the cryopreserved cord blood units contain sufficient stem cells to reconstitute an adult. These aspects were extensively probed at the trial, and witnesses explained the various claim limitations and the prior art.

The district court, on post-trial motions, held that the jury verdict that the claims are not anticipated was supported by substantial evidence. The court referred to testimony of the expert witnesses for both sides, who agreed that Koike did not show hematopoietic reconstitution using cord blood, and that Koike did not enable transplantation. The defendant’s expert witness testified (on cross-examination) that Koike’s small samples could not contain a therapeutic amount of stem cells, and that the Koike article does not reflect knowledge of stem cells or indicate their presence to persons of skill in the field or show how to achieve transplantation of cord blood cells. As explained in In re Donohue, 766 F.2d 531, 533 (Fed.Cir.1985), possession of the invention adequate to show anticipation requires that a person of ordinary skill in the field of the invention would discern every element of the invention in the allegedly anticipating reference, and know how to carry it out based on the state of knowledge at the time of the reference. See, e.g., Elan Pharms., Inc. v. Mayo Found., 346 F.3d 1051, 1054 (Fed. Cir.2003) (a claim “cannot be anticipated by a prior art reference if the allegedly anticipatory disclosures cited as prior art are not enabled”). There was substantial evidence that Koike did not establish that there were stem cells in umbilical cord blood nor teach a therapeutic composition for use in hematopoietic reconstitution of a human adult.

The '681 patent describes the prior art in detail, including the following with respect to stem cells in human umbilical cord blood:

A human hematopoietic colony-forming cell with the ability to generate progenitors for secondary colonies has been identified in human umbilical cord blood (Nakahata, T. and Ogawa, M., 1982, J. Clin. Invest. 70:1324-1328). In addition, hematopoietic stem cells have been demonstrated in human umbilical cord blood, by colony formation, to occur at a much higher level than that found in the adult (Prindull, G., et al., 1978, Acta Paediatr. Scand. 67:413-416; Knudtzon, S., 1974, Blood 43(3):357—361).

'681 patent, col. 4, lines 15-24. The '681 patent explains that the differences between stem and progenitor cells are operational and depend on functional rather than on morphological criteria. Col. 3, lines 4-39. In functional assays, stem cells can be identified by spleen colony forming units (CFU-S), whereas multipotent progenitor cells can be identified through colony-forming unit-granulocyte, erythrocyte, monocyte/macrophage, megakaryocyte (CFU-GEMM) relatively differentiated progenitor cells through colony-forming unit-granulocyte, macrophage (CFU-GM) and burst-forming unit-erythroid (BFU-E). Id. at col. 26, lines 1-16. Koike, in determining the viability of the cryopre-served fetal bone marrow and cord blood, employed CFU-GM and BFU-E assays to measure progenitor cells, not stem cells.

The patent examiner concluded, and witnesses at trial testified, that the Koike reference is directed to progenitor cells, not stem cells. The reexamination record was in evidence, wherein the examiner stated:

The remaining references that recited umbilical cord blood, specifically the Koike and Vidal references, recited the cryopreservation of a Ficoll-Hypaque fraction of umbilical cord blood and did not provide any evidence that viable human neonatal or fetal hematopoietic stem cells were present in the thawed samples.

Notice of Intent to Issue Reexamination Certificate at 4 (Jan. 11, 2000). The examiner observed that Koike did not mention stem cells and did not show or enable transplantation to an adult, and that although Koike postulated that cord blood may be a source of hematopoietic progenitor cells, Koike did not show how or if such use could be achieved. The examiner’s reasons for allowance included the following:

... Since hematopoietic stem cells engage in both replication and differentiation, the presence of progenitors (differentiated stem cells) is not predictive of the presence of stem cells. All of the prior art references which taught the cryopreservation of a Ficoli-Hypaque fraction of umbilical cord blood assayed for the presence of progenitor cells and merely theorized on the presence of stem cells. None of the prior art references demonstrated the presence of stem cells in the umbilical cord blood.

Id. When the reference relied on at trial was before the patent examiner, a reasonable jury may give weight to the examiner’s view of the reference when deciding whether invalidity has been proved by clear and convincing evidence. See Hewlett-Packard Co. v. Bausch & Lomb Inc., 909 F.2d 1464, 1467 (Fed.Cir.1990) (referring to the particularly heavy burden in establishing invalidity on the same prior art that was examined in the PTO).

The defendants argue that it is irrelevant whether Koike described or recognized the presence of stem cells in cord blood, because they were inherently there. However, as discussed in Turbo-Care Div. of Demag Delaval Turboma-chinery Corp. v. General Electric Co., 264 F.3d 1111, 1119 (Fed.Cir.2001), “[i]n order for a disclosure to be inherent, ‘the missing descriptive matter must necessarily be present in the [original] applicant’s specification such that one skilled in the art could recognize such a disclosure,” (quoting Tronzo v. Biomet, Inc., 156 F.3d 1154, 1159 (Fed.Cir.1998)). As the district court pointed out and as the expert witnesses testified, Koike does not show the claim limitations to therapeutic compositions or that the cryopreserved blood units must be from a single human or that stem cells must be present in an amount sufficient for hematopoietic reconstitution of a human adult, or suggest how to conduct a successful transplantation. Witnesses testified that persons in this field of science did not have the knowledge to routinely fill these omissions, and reinforce the examiner’s statement that “the presence of progenitors (differentiated stem cells) is not predictive of the presence of stem cells.” See Reexamination Notice of Intent, supra; see also Elan Pharmaceuticals, 346 F.3d at 1057 (discussing the need for evidence on the question of whether the reference placed a person of ordinary skill in possession of the invention as claimed); Rosco, Inc. v. Mirror Lite Co., 304 F.3d 1373, 1380 (Fed.Cir.2002) (“Under the doctrine of inherency, if an element is not expressly disclosed in a prior art reference, the reference will still be deemed to anticipate a subsequent claim if the missing element ‘is necessarily present in the thing described in the reference, and that it would be so recognized by persons of ordinary skill.’ ”) Particularly when the science or technology is new or complex, a bare suggestion or hope that requires significant experimentation for implementation or verification is not an invalidating “anticipation” of that which is ultimately achieved.

These aspects were explored at the trial, with witnesses for both sides agreeing that it was not known, at the time of the Koike reference, how to use cord blood for marrow transplantation and human reconstitution. The district court concluded that a reasonable jury could have found that no single reference described all of the '681 patent claim limitations, explicitly or inherently. The panel should review this issue in the interest of finality, and rule that the verdict that anticipation of the '681 claimed invention had not been established was supported by substantial evidence, and was properly sustained by the district court.

The '553 claims are directed to method steps, including the step of introducing the stem cells into a human host. The district court summarized the evidence as follows:

It is undisputed that Koike did not introduce cord blood into a human, which is a necessary limitation of the '553 Patent. The defendants claim that Koike’s suggestion that introducing the stem cells into a human host should be done is a sufficiently enabling disclosure to warrant a finding of anticipation. Even so, the record contains substantial evidence from which a jury could find that a person of ordinary skill in the art would not have been so enabled.

Pharmastem Therapeutics, Inc. v. Viacell, Inc., 2004 WL 2898061 at *4 (D.Del.2004).

The defendants argue that Koike is as enabling as the patents in suit — an argument that could well have been rejected by the jury, for the '681 patent describes extensive animal transplantation experiments and shows surrogate assays of over one hundred cord blood units, and the '553 patent includes details of the transplantation of cryopreserved fetal cord stem cells to reconstitute the blood of a five-year-old child who was suffering from Fanconi’s Anemia; in contrast with the absence of any such information in the Koike reference. The district court held that there was substantial evidence whereby a reasonable jury could have found that the Koike reference did not anticipate the '553 claims. I agree. The panel should review and resolve this issue, which was fully appealed, in the interest of finality.

Indeñni teness

A similar obligation applies to the cross-appeal of validity on the ground of indefiniteness. The matter was fully presented on the appeal to this court, and warrants resolution.

The defendants challenged both patents under 35 U.S.C. § 112, arguing that the claims are indefinite because, at the time the patent applications were filed, stem cells in umbilical cord and placental blood could not be identified and the stem cell content could not be measured. The defendants’ position is that measurement of stem cell content required actually transplanting the blood into a host and observing its effect, and that since the '681 composition claims require stem cells “in an amount sufficient to effect hematopoietic reconstitution of a human adult,” the defendants could not know if they were infringing the claims. PharmaStem’s position is that surrogate animal tests, as shown in its patents, adequately measure stem cell content. PharmaStem points out that the defendants all test the cord blood before placing it in storage and when releasing it for transplant. The jury found that the claims were not invalid on this ground, answering Question No. 10:

Question No. 10
Have the Defendants proven by clear and convincing evidence that the '681 patent is indefinite in that on November 12,1987, a person of ordinary skill in the art would not have been able to determine from the patent what the claimed invention covers?
YES _ NO _X_

Witnesses explained at the trial that the '681 specification describes the conduct of surrogate assays and their use to test for stem cells, and correlates the surrogate assays with therapeutic stem cell effect. Reviewing the evidence, the district court referred to the expert testimony of Dr. Malcolm Moore, a cell biologist, that the patents provide “ample information to determine the amount of cord blood needed for transplant in adults and children, and that the scientific community has in fact performed numerous transplants into adults. Moore Tr. at 340-348.” Pharmastem, 2004 WL 2898061 at *5.

Section 112 requires that the claims point out “the subject matter which the applicant regards as his invention,” implementing the purpose of claims to identify what has been invented and found patentable, so that “one skilled in the art would understand the bounds of the claim when read in light of the specification.” Miles Laboratories, Inc. v. Shandon, Inc., 997 F.2d 870, 875 (Fed.Cir.1993) (“If the claims read in light of the specification reasonably apprise those skilled in the art of the scope of the invention, § 112 demands no more.”)

The courts have recognized, particularly in fields of new and evolving knowledge, that the claims can be no more precise than the knowledge in the field permits. See Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1385 (Fed.Cir.1986) (“ ‘if the claims, read in light of the specification, reasonably apprise those skilled in the art both of the utilization and scope of the invention, and if the language is as precise as the subject matter permits, the courts can demand no more’ ”) (quoting Shatterproof Glass Corp. v. Libbey-Owens Ford Co., 758 F.2d 613, 624 (Fed.Cir.1985)). See also, e.g., Marley Mouldings, Ltd. v. Mikron Indus., 417 F.3d 1356, 1361 (Fed.Cir.2005) (when a claim “is not insolubly ambiguous, it is not invalid for indefiniteness”); Exxon Research & Eng’g Co. v. United States, 265 F.3d 1371, 1375 (Fed.Cir.2001) (“if the meaning of the claim is discernible, even though the task may be formidable and the conclusion may be one over which reasonable persons will disagree, we have held the claim sufficiently clear to avoid invalidity on indefiniteness grounds”). The defendants argue that even if this criterion is met, it is inadequate to satisfy § 112 in this case because the defendants had no way of being certain whether any unit of cord blood infringed the claims. The defendants argue that even if the science later evolved so that stem cell content could be directly measured, such information did not exist when the '681 application was filed.

To patent an invention when the science or technology to which it is directed is incompletely developed or understood, requires that it be described and claimed in terms adequate to communicate, to persons experienced in the field of the invention, what has been discovered. The '681 patent states that “any of numerous assays for hematopoietic stem or progenitor cells may be used.” Col. 25, lines 49-50. For example:

[A]n item cell assay for CFU-S (colony forming unit-spleen) can be done. In this assay, cells considered to be multi-potential stem cells with self-renewal capacity can be measured by counting the number of colonies (nodules) on the spleen(s) of lethally-irradiated mice that have been inoculated with a composition containing the cells.

Col. 26, lines 1-7. The CFU-S assay is done essentially the same way as progenitor cell assays such as BFU-E/CFU-GEMM and CFU-GM assays. Col. 48, lines 42-43. The specification states:

A survey of published reports indicates that the number of CFU-GM infused for autologous bone marrow reconstitution in human patients, can be relied on as an indicator of the potential for successful hematopoietic reconstitution (Spitzer, G., et al., 1980, Blood 55(2): 317-323; Douay et al., 1986, Exp. Hematol. 14:358-365). By standardizing published data by patient weight, and assuming a patient weight of 150 pounds (67.5 kilograms), the calculated number of CFU-GM needed for successful hemato-poietic reconstitution using autologous bone marrow cells ranges from 2-425 x 104, with faster recovery noted using greater than 10 x 104 CFU-GM.

Col. 50, line 64 to col. 51, line 8. The expert testimony at trial explained this and other descriptive text, whereby a reasonable jury could have concluded that the assays described in the patent serve to ascertain whether sufficient amounts of stem cells are present in the preserved cord blood to reconstitute the host.

It was not disputed that the information in the specification is as definite as the state of scientific knowledge at the time of filing. It has been recognized that the “existence of an inescapable area of uncertainty is not sufficient justification for denying to the patentee the fruits of his invention.” Ga.-Pac. Corp. v. U.S. Plywood Corp., 258 F.2d 124, 136 (2d Cir.1958) (“the policy of the patent statute contemplates granting protection to valid inventions, and this policy would be defeated if protection were to be accorded only to those patents which were capable of precise definition. The judicial function requires a balancing of these competing considerations in the individual case.”) The district court fulfilled this judicial function, stating, in denying the defendants’ motion for JMOL, that: “Given that there is no determinate or determinable minimum amount of cord blood for therapeutic usefulness in humans, the record supports that the '681 claim language is as precise as the subject matter permits.” Pharmastem, 2004 WL 2898061 at *5 (citing Hybritech, supra). As the district court ruled, there was substantial evidence whereby the jury could have found that the claims of the '681 and '553 patents would be understood by persons in the field of the invention. The verdict that the claims are not invalid for indefiniteness should be sustained, and should be reviewed, not left dangling on appeal.

Obviousness

The ultimate solution of a previously intractable problem can indeed appear to become apparent in hindsight after the final successful step is taken. Yet that final step in this case was not taken by those who came before, and was clearly not “obvious” to contemporaries, who acclaimed the achievement. Even the defendants’ expert witness acknowledged that before the work of these inventors “stem cells could not be conclusively proved to be present in cord blood.” Maj. op. at 1362. Nonetheless this court rejects the testimony and admissions of the defendants, and uses present knowledge of the inventors’ success to find that it was obvious all along.

When trial is to a jury, the court instructs the jury as to the applicable law, and the jury applies the law to the facts as it finds them. Appellate review is on the standard of determining whether there was substantial evidence to support the jury’s express or presumed factual findings, and whether the jury applied the correct law to those findings. See C.R. Bard, Inc. v. M3 Systems, Inc., 157 F.3d 1340, 1351-52 (Fed.Cir.1998) (“We review a jury verdict of obviousness to determine whether substantial evidence supports the factual findings predicate to the legal conclusion of obviousness and whether such findings can support the verdict, with appropriate consideration of the presumption of validity and the requirement that obviousness be proved by clear and convincing evidence; factual inferences are drawn and credibility determinations are accepted in favor of the verdict winner”) The question is whether the jury’s verdict is sustainable on the evidence presented, not whether we could have or would have gone the other way on the evidence presented.

The jury answered “NO” to the question whether the '681 and '553 claimed inventions “would have been obvious to a person of ordinary skill in the field of the invention.” Responding to the defendants’ challenge to the verdict, PharmaStem points to the evidence of the extensive research in this field of science — much of which is set forth in the patent specifications — and to the specific claim limitations. The broadest composition claim (the '681 patent) is as follows:

1. A cryopreserved therapeutic composition comprising:
viable human neonatal or fetal hema-topoietic stem cells derived from the umbilical cord blood or placental blood of a single human collected at the birth of said human,
in which said cells are present in an amount sufficient to effect hematopoietic reconstitution of a human adult;
and an amount of cryopreservative sufficient for cryopreservation of said cells.

This claim was the subject of two reexaminations, one preceding this litigation, the second completed during the past year. For the first reexamination, the examiner’s reasons for allowance included the following:

The claims as amended now avoid the prior art for the following reasons. First, it was noted that the only piece of prior art which taught a composition which could have combined an amount of viable human neonatal or fetal hemato-poietic stem cells sufficient to effect he-matopoietic reconstitution of a human adult was the reference of Ende. The Ende reference, published in 1972, recited the treatment of an individual undergoing treatment for leukemia who received a series of cord blood infusions from multiple donors and showed a transient change in red blood cell phenotype. Even though the authors of the Ende article describe the procedure as “transplantation,” it is clear that such treatment did not result in hematopoietic reconstitution. Further, since no HLA typing was performed, and multiple infusions were performed, one of ordinary skill in the art would have taken the disclosure of Ende to be equivalent to blood transfusions and would have had no expectation that the hematopoietic reconstitution of a human adult could have been performed. As a transfusion composition, one of ordinary skill would have had no motivation to cryopreserve the cord blood, since whole blood for transfusion is not frozen, but stored st 4°C and Ende further points out that any hospital with a maternity ward would provide sufficient aliquots of fresh cord blood.

Notice of Intent to Issue Reexamination Certificate at 3-4 (Jan. 11, 2000). The examiner discussed the state of the science, the content of the prior art, the known sensitivity of fetal liver and thymus stem cells to freezing, and the unpredictability of this field, and concluded:

This disclosure combined with the acknowledged sensitivity of hematopoietic stem cells from fetal liver and thymus to cryopreservation and the fact that DMSO is toxic to fetal liver progenitor cells at concentrations nontoxic to bone maiTOw cells provides an unpredictability in the art of cryopreservation of stem cells from different sources that renders the suggestions of the prior art references as to the therapeutic uses of umbilical cord blood (whether eryopre-served or not) as a course of hemato-poietic stem cells a situation of “obvious to try,” which fails to provide a prima facie finding of obviousness....

Id. at 4.

For the second reexamination, the examiner discussed additional arguments involving the same references on which this court now relies to invalidate the patent:

At the time of the instant invention the use of cord blood for hematopoietic reconstitution had never been accomplished. Additionally, in vitro expansion of cord-blood stem cells prior to patient implantation had not been successfully employed, and indeed is not in use as of today as indicated by the Dr. Zander declaration. Accordingly, determination of a pharmaceutically efficacious and safe dosage that results in human adult hematopoietic reconstitution would necessarily require undue experimentation, thus precluding enablement. In this respect, it was patentee’s in vitro progenitor assays taken in conjunction with in vitro mice testing showing hematopoietic reconstitution with a relatively small amount of neonatal blood, that provided the necessary teaching to enable the obtaining of effective hematopoietic reconstituting dosages in children (extrapolatable to adults) by utilizing cord blood volumes (50-100 ml) derived from a single adult. Thus, neither the Koike reference taken alone anticipates, nor a combination of references render obvious, the instantly claimed invention.

Reexamination — Reasons for Patentability/Confirmation (Dec. 29, 2006). No error has been shown in this analysis, which warrants deference in accordance with the strictures of the Administrative Procedure Act. See Dickinson v. Zurko, 527 U.S. at 164, 119 S.Ct. 1816 (“A reviewing court reviews an agency’s reasoning to determine whether it is “arbitrary” or “capricious,” or, if bound up with a record-based factual conclusion, to determine whether it is supported by “substantial evidence.” ”), citing SEC v. Chenery Corp., 318 U.S. 80, 89-93, 63 S.Ct. 454, 87 L.Ed. 626 (1943).

The record contains testimony that scientists working in the field of hematopoietic reconstitution did not expect cord blood to be a successful transplant tissue or a useful source of hematopoietic stem cells. There was testimony that earlier efforts at using cord blood had encountered problems, and that there was skepticism and surprise at the inventors’ achievement. The reaction of scientific peers after the achievement is relevant to whether the invention would indeed have been obvious at the time it was made. See Cardiac Pacemakers, Inc. v. St. Jude Medical, Inc., 381 F.3d 1371, 1376 (Fed.Cir.2004) (evidence of skepticism that the multi-mode treatment of the invention could be achieved supported the jury verdict of non-obviousness); Metabolite Laboratories, Inc. v. Laboratory Corp. of America Holdings, 370 F.3d 1354, 1368 (Fed.Cir.2004) (evidence that skilled artisans were initially skeptical about the invention supported the jury’s verdict of nonobviousness).

The significance of the inventors’ work was in evidence, including their founding of Biocyte and spawning of the industry of collecting and cryofreezing umbilical cord blood. In evidence was defendant Via-Cord’s “business plan” which identified these inventors as “the trailblazers”:

The founding scientists are core researchers in this field and have published many related articles. Biocyte’s time, energies, and financial resources have been spent doing much education and development in this field. They are the trailblazers.

A communication to these inventors from the founder of defendant Cryo-Cell stated:

[N]o one will ever dispute that you, as the pioneers in the medical technology ... will be the frontrunners in the field of utilizing of the blood from the umbilical cord for restoring hematopoietic through marrow transplants.

Such evidence assists in replacing judicial hindsight with objective determination as of the time of the invention. See Vandenberg v. Dairy Equip. Co., 740 F.2d 1560, 1567 (Fed.Cir.1984) (in “determining the question of obviousness, inquiry should always be made into whatever objective evidence of nonobviousness there may be”). In Graham v. John Deere Co., 383 U.S. 1, 17-18, 36, 86 S.Ct. 684, 15 L.Ed.2d 545 (1966) the Court counseled that “Such secondary considerations as commercial success, long felt but unsolved needs, failure of others, etc., “serve to guard against slipping into use of hindsight and to resist the temptation to read into the prior art the teachings of the invention in issue,” ” cited in KSR v. Teleflex, 127 S.Ct. at 1734.

PharmaStem’s expert, Dr. Bernstein, testified that no prior art showed that cord blood contains stem cells, and that persons of skill in this field would not have had a reasonable expectation of success in carrying out the claimed process. Dr. Bernstein also discussed the early uncertainties and mistaken understanding concerning stem and progenitor cells. His testimony is now disputed by this court, denying it the weight that a reasonable jury could have given it. Dr. Bernstein had explained at the trial that at the time of filing the patent application the differences between stem cells and progenitor cells could not be measured and were not well understood. The jury could have accepted this testimony, and indeed the defendants did not refute it; but the panel majority now holds that the inventors’ apparently inconsistent use of stem and progenitor terminology constitutes an “admission! ] in the specification regarding the prior art” which is then “binding on the patentee for purposes of a later inquiry into obviousness.” Maj. op. at 1362. This is not a simple issue, but the jury could reasonably have concluded, as did the district court, that the prior art did not show that there were stem cells in cord blood, and that one of ordinary skill in this field would not have had a reasonable expectation of successful use of cord blood to reconstitute a human adult.

A reasonable jury could have found that these inventors were not simply conducting a routine optimization, as my colleagues now rule on what they describe as the “more difficult question [of] whether the prior art would have given rise to a reasonable expectation of success in creating the [claimed inventions].” My colleagues state that they are “plainly satisfied” that “a person of ordinary skill in the art would have had reason to attempt to make [the claimed inventions].” I agree that there was reason to seek a cure for destroyed blood cells, and that scientists have been seeking such a cure for a long time, including those scientists whose work is the cited prior art. There has been much hopeful speculation about the potential of stem cells, although this remedy eluded those who came before.

It is often far easier to recognize the problem than to find and demonstrate the solution. The patent law recognizes that advances of great power may be based as much on persistent and skilled investigation as on the flash of creative genius, for both serve to transcend that which was previously achieved. See 35 U.S.C. § 103 (“Patentability shall not be negatived by the manner in which the invention was made.”) My colleagues go too far in limiting the patent system to the serendipitous and the unexpected. Maj. op. at 1363 (“while their work may have significantly advanced the state of the science of hema-topoietic transplantations by eliminating any doubt as to the presence of stem cells in cord blood,” they “merely used routine research methods to prove what was already believed to be the case”). Further, these scientists not only established the presence of stem cells, but also enabled their development for preservation and he-matopoietic reconstitution.

The court’s approach reflects misperception of the scientific process as well as the patent purpose. Scientific methodology usually starts with a hypothesis based on what is already known; the record shows that several scientists mentioned the idea of rebuilding destroyed blood cells. However, none achieved this long-sought goal, and the record shows the extreme skepticism concerning even the possibility of this achievement. The district court found that there was “tremendous skepticism in the transplant field regarding the use of cord blood as a transplant tissue,” and that the jury could have found that “prior to the inventions of the Patents-in-suit, those in the field of hematopoietic reconstitution would not have expected cord blood to be a successful transplant tissue.”

Nonetheless, my colleagues deny the value of this long-sought result, whereby for the first time umbilical blood was preserved and recovered and used to reconstitute the hematopoietic systems in mammals, demonstrated with the mice experiments reported in the '681 patent, and the human transplant in the '553 patent. Not even the defendants denigrate the inventors’ achievement as “merely supporting evidence” for an “expected” result, as in the maj. op. at 1365. Even if this court were not required to recognize the substantial evidence in support of the jury verdict, even if APA deference were not required to the three PTO reexaminations, one must pause at the powerful evidence of the acclaim that was accorded to this achievement, by these defendants as well as by scientific peers.

There was substantial evidence whereby the jury could have sustained the unobvi-ousness of the '681 and '553 inventions. I must, respectfully, dissent from the panel majority’s invalidation of these patents on this ground.

INFRINGEMENT

The jury found infringement of the '681 and '553 patents. In determining whether substantial evidence supported the verdict, the evidence before the jury and all reasonable inferences therefrom must be viewed in the light that is favorable to the verdict, without substituting the court’s view of the evidence for that of the jury. Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 254-55, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986); see SIBIA Neurosciences, Inc. v. Cadus Pharm. Corp., 225 F.3d 1349, 1355 (Fed.Cir.2000) (“In reviewing the record, we must draw all reasonable inferences in favor of the prevailing party, and not make credibility determinations or substitute our view of the conflicting evidence for that of the jury.”) My colleagues, like the district court, grant JMOL on a ruling of law and evidence that was not presented to the jury, and that in all events does not support reversal of the verdict.

My colleagues appear to hold that infringement cannot be found because the cryopreserved cord blood “relates only as possibilities” for “future use in adult transplants.” Indeed, this entire system is designed for possible future needs of the infant itself or family members. The defendants’ testimony was uniformly to the effect that this “possibility” was the purpose of their preservation service (the record also describes a case in which the cord blood was used to treat the mother’s existing disease). The evidence was that most but not all of the cryopreserved cord blood that has been transplanted was to children, with about ten percent transplanted to adults. PharmaStem is correct that this ratio relates to damages, and does not simply serve to negate all liability for infringement.

The district court ruled that PharmaS-tem had not proved infringement because PharmaStem did not separately analyze the stem cell content of each sample of cord blood. PharmaStem presented evidence that separate analysis was unnecessary because each defendant had analyzed each sample before accepting it for storage. Every defendant testified that the blood it collected and stored was analyzed for cell content at the time of collection. The jury was not instructed that such evidence was inadequate and inadmissible— as the district court ruled post-trial. On the evidence presented, this is not a sound basis for rejecting the jury’s verdict. The tardy rejection of the testimony of Phar-maStem’s expert witness, Dr. Hendrix, is an inappropriate application of Daubert and its succeeding cases, on which the panel majority relies, for there was no criticism of the expert’s scientific credentials or her analysis of the prior art and the state of the science. See Daubert v. Merrell Dow Pharms., 509 U.S. 579, 590, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993) (for a scientific assertion to “qualify as ‘scientific knowledge,’ an inference or assertion must be derived by the scientific method”); Kumho Tire Co. v. Carmichael, 526 U.S. 137, 119 S.Ct. 1167, 143 L.Ed.2d 238 (1999) (the principles of Daubert apply broadly to “scientific, technical, or other specialized knowledge”).

The district court’s ground of exclusion was not that Dr. Hendrix made an error of law or of scientific fact, but simply that she also stated her opinion concerning the defendants’ marketing statements that they test and preserve cord and neonatal blood for possible future child and adult use— testimony that the district court criticized because it did not require scientific expertise. Whatever the virtue of that criticism, it is clear that the district court’s (and my colleagues’) exclusion of the entire testimony of this eminent scientist on this ground is not what the Daubert ruling is about. There was no testimony contrary to the view of Dr. Hendrix of the scope of the representations made in the marketing materials, and no challenge to the accuracy of her statements. Presentation of expert testimony was in compliance with the general rule that “typically expert testimony will be necessary in cases involving complex technology,” Centricut, LLC v. Esab Group, Inc., 390 F.3d 1361, 1370 (Fed.Cir.2004), and this expert’s testimony did not cross the boundaries of admissibility.

The '681 Patent

The district court granted JMOL of non-infringement of the '681 patent on the ground that PharmaStem had not proved that 100% of the defendants’ preserved cord and neonatal blood contained sufficient stem cells to reconstitute an adult. The district court reasoned that since PharmaStem took the litigation position that it was entitled to damages measured as a royalty based on 100% of the preserved blood, to prove infringement Phar-maStem had to prove that 100% of the preserved blood contained sufficient stem cells to provide adult reconstitution, by analyzing 100% of the preserved blood. As I have mentioned, PharmaStem complains that this criterion differed from that on which the jury was instructed, and also states that even this criterion was met by substantial evidence presented at the trial.

My colleagues, overturning the jury verdict, hold that there is no infringement of the '681 patent because PharmaStem did not retest every unit of stored blood to determine its stem cell content. They ignore the evidence that every unit was tested by each defendant before being placed into cryogenic storage; every defendant so testified. It was not disputed that retesting of every unit could use up a significant amount of the precious preserved blood. No defendant asserted that it routinely cryogenically preserved cord blood that did not contain sufficient stem cells to be potentially useful for hematopoietic reconstitution. A reasonable jury could have considered this evidence to find that each element of the claims was met. Instead, my colleagues simply rule that without testing of the stored units there can be no liability at all. That evidentiary theory was not presented to the jury; it is too late to criticize as legally inadequate the testimony that was based on the defendants’ own representations concerning the content of the stored umbilical and neonatal blood.

The verdict of infringement was supported by the defendants’ own testimony setting forth their requirements for stem cell content before accepting cord blood for cryopreservation. For example, defendant CBR’s Scientific Director testified that every unit of cord blood presented to CBR for storage is tested to see if it contains a sufficient amount of stem cells to have “a good probability of being useful in the clinical setting.” In evidence were CBR’s website statements that “transplants have occurred for the newborn himself, the newborn’s mother, father, and the newborn’s cousin,” and “umbilical cord blood from unrelated donors can restore hematopoies-is in adults who receive myeloablative therapy and associated with acceptable rates of severe acute and chronic GVHD [Graft vs. Host Disease].”

The President of defendant CorCell testified that “what our marketing materials state [is] that it may be used to treat the donor or siblings or potentially parents,” and that although only one CorCell stored cord blood unit had thus far been transplanted, that transplant was to an adult. There was testimony that CorCell’s cord blood samples are tested for “total nucleated, CD-344- and viability cell counts before and after processing,” and “a colony-forming assay is conducted to evaluate the quality and quantity of umbilical stem cells,” and that a sample is usually not preserved if its stem cell content is determined to be unsuitable for possible future use. The jury was shown CorCell’s representation to investors that “a recent study of twenty-five (25) patients, published in the New England Journal of Medicine, similarly indicates that cryopreserved umbilical cord blood stem cells can be successfully engrafted in children and adults with a variety of hematologic or immunologic disorders.” The jury saw evidence that CorCell defines potential recipients of the stored stem cells as “the family members of the newborn, mother, father, siblings and possibly grandparents.”

Defendant ViaCell’s founder testified that each cord blood sample was tested to ensure that there is a sufficient amount of stem cell content to be therapeutically useful, as determined by ViaCell’s Scientific Advisory Board. ViaCell’s Senior Vice President testified that ViaCell counts the cells in every collected sample, and that its standard procedure states: “A minimum total NC count of 3.0 x 108 is required to proceed with processing.” A ViaCell memorandum to investors stated that about 10% of all cord blood transplants were in adults, and a ViaCell witness testi-fled that ViaCell informs the public about adult use.

At the trial none of the defendants denied the stem cell content of the blood they eryopreserved, other than to state that for the few cases where their analysis at collection showed weak stem cell content they would consult with the infant’s family before accepting and freezing the blood. The jury heard the defendants’ testimony and unqualified representations concerning their screening of every stored sample of cord blood for stem cell content, and that they did not distinguish between potential child and adult use of the stem cells. The jury could have relied on the defendants’ testimony that their minimum threshold for cryopreservation is sufficient stem cells for transplantation, and that all of the defendants included possible adult use in their publicly-stated reasons for storing fetal cord and neonatal blood. PharmaS-tem points out that it was neither necessary nor prudent to test each unit of the defendants’ stored blood for stem cell content, when each defendant had already done so.

The jury was instructed: “A defendant is liable for directly infringing PharmaS-tem’s patents if you find that PharmaStem has proven by a preponderance of the evidence that they have made, used, offered for sale or sold a composition that includes each and every element of at least one of the asserted claims of the '681 patent.” The theory that each stored sample had to be separately analyzed by Phar-maStem to show infringement was not presented as law to the jury. This was a new standard for infringement, for the jury was not told that the defendants’ analyses of stem cell content could not provide evidence of stem cell content.

When there is substantial evidence in support of the jury’s verdict, it is irrelevant whether the appellate court would have preferred different or additional evidence. “When the jury is supplied with sufficient valid factual information to support the verdict it reaches, that is the end of a matter .... the jury’s factual conclusion may not be set aside by a JMOL order.” McGinley v. Franklin Sports, Inc., 262 F.3d 1339, 1355 (Fed.Cir.2001). The district court erred in holding that it was necessary for PharmaStem to analyze, or provide detailed analysis results, for the individual blood units in order to find infringement. My colleagues commit the same error, reweighing the evidence to reach their preferred result, rather than considering whether substantial evidence as presented at the trial supports the verdict that was reached by the jury.

The '553 Patent

It was agreed at trial that the claims of the '553 patent are not infringed until the step of transplanting the stem cells takes place. Since relatively few transplants of stored blood had been done, the royalties awarded by the jury were modest, and were not appealed. However, the verdict of infringement is supported by substantial evidence, and should stand. There was substantial evidence that each step of the claimed invention is performed by the defendants followed by a transplant surgeon. Referring to claim 13, the defendants isolate the umbilical cord and placental blood containing stem cells and cryopreserve it in liquid nitrogen; claim clauses (a) and (b). When instructed on behalf of the donor or family members, the blood is delivered to a surgical environment where it is thawed, claim clause (c), and transplanted into the human host, claim clause (d):

13. A method for hematopoietic or immune reconstitution of a human comprising:
(a) isolating human neonatal or fetal blood components containing hemato-poietic stem cells;
(b) cryopreserving the blood components;
(c) thawing the blood components; and
(d) introducing the blood components into a suitable human host, such that the hematopoietic stem cells are viable and can proliferate within the host.

The jury found the defendants liable for “acting in concert or working together” with the transplant physicians, or contributing to the infringement of the '553 patent, upon answering the following questions:

Question No. S: Substantial Non-Infringing Use
Has PharmaStem proven by a preponderance of the evidence that cryopreserved cord blood has no substantial noninfringing use?
YES _X_ NO_
Question No. f: Direct Infringement
Has PharmaStem proven by a preponderance of the evidence that defendants and the transplant physicians are acting in concert or working together to complete the process of infringement of claims 13, 19, 47, 53, or 57 of the '553 patent by performing each and every one of the steps in any of those claims?
YES _X NO_
Question No. 5: Contributory Infringement
Has PharmaStem proven that a defendant has contributorily infringed the '553 patent by selling or offering to sell cryopreserved cord blood that was actually used by a third party in the direct infringement of any of claims 13, 19, 47, 53, or 57 of the '553 patent?
Answer separately for each defendant.
ViaCell YES X_ NO _
CBR YES _X_ NO_
Cryo-CellYES X_ NO_
CorCell YES X_ NO _

PharmaStem thus received special verdicts of both direct joint infringement and contributory infringement. My colleagues grant JMOL on the ground that since the defendants are providing a service, not selling a product, they can not meet the “sale” requirement of contributory infringement, 35 U.S.C. § 271(c). Phar-maStem points out that a reasonable jury could have found that the defendants sell (rent) their blood-storage facilities to the donor’s family, and that the defendants either contribute to or act in concert with the transplanting surgeon to practice the claimed method.

The principles of patent infringement are not negated when the steps of a method claim are performed by more than one entity. There was no instruction as to legal impossibility of liability as to the '553 patent, and no objection was raised to the verdict questions. We are not told whether the legal theory of sale or rent was aired at the trial, but it is apparent that the jury was fully apprised of the nature of the accused activities, as reflected in the jury questions. The processes of litigation require appellate review on the premises of the jury trial, lest invited error dominate trial tactics.

No objection was raised to the jury instructions. The distinction relied on by the panel majority, that the defendants were bailees, not sellers, does not negate the principles of infringement, whether viewed as joint infringement or contributory infringement. See, e.g., On Demand Machine Corp. v. Ingram Indus., Inc., 442 F.3d 1331, 1334 (Fed.Cir.2006) (approving instruction that “It is not necessary for the acts that constitute infringement to be performed by one person or entity”) Phar-maStem is correct that the issue to which this evidence applies relates to damages, not infringement, and points to the small amount of damages awarded for infringement of the '553 patent (damages for the '553 patent were not appealed by the defendants).

It is irrelevant whether any steps of a method claim can be viewed as a “service;” infringement requires only that the steps be performed. As discussed in Dawson Chemical Co. v. Rohm and Haas Co., 448 U.S. 176, 188, 100 S.Ct. 2601, 65 L.Ed.2d 696 (1980), the purpose of the contributory infringement statute is “to protect patent rights from subversion by those who, without directly infringing the patent themselves, engage in acts designed to facilitate infringement by others,” a criterion that the jury could have found was met by the facts and relationships of this case. On the instructions to the jury, the verdict of liability for contributory or joint infringement of the '553 patent is supported by substantial evidence, and should be sustained.

From the court’s departure from the procedures of appellate review of jury verdicts, and from the flawed law that is propounded, I must, respectfully, dissent. 
      
      . The parties and the district court discussed the issue of joint infringement in the context of determining whether there was infringing conduct sufficient to serve as a predicate for a finding of contributory infringement. Phar-maStem did not argue before the district court, and does not argue here, that liability could be premised on a theory of "joint” or "divided” infringement, even in the absence of a finding of contributory infringement under 35 U.S.C. § 271(c). Under that theory, two related parties are both deemed liable for direct infringement of a method patent when each performs some steps of the claimed method. The viability and scope of that theory of liability is a subject of considerable debate; it has been addressed in a number of district court cases, adverted to in a few of this court's cases, and discussed at some length by commentators. See On Demand Mach. Corp. v. Ingram Indus., Inc., 442 F.3d 1331, 1334 (Fed.Cir.2006); Cross Med. Prods., Inc. v. Medtronic Sofamor Danelc, Inc., 424 F.3d 1293, 1311 (Fed.Cir.2005); Kristin E. Gerdelman, Subsequent Perfonnance of Process Steps by Different Entities: Time to Close Another Loophole in U.S. Patent Law, 53 Emory L.J.1987 (2004); Mark A. Lemley et al., Divided Infringement Claims, 33 AIPLA QJ. 255 (2005); Sriranga Veeraraghavan, Joint Infringement of Patent Claims: Advice for Pat-
        
        eniees, 23 Santa Clara Computer & High Tech L.J. 211 (2006). That issue is squarely presented in a case now pending before this court, BMC Resources, Inc. v. Paymentech, L.P., No.2006-1503. In this case, PharmaS-tem’s theory of liability was that the defendants were liable under section 271(c) for contributory infringement, not under section 271(a) for direct infringement, and PharmaS-tem has continued to press that theory on appeal. We therefore are not presented with the question whether the defendants could have been held liable under section 271(a) under a theory of joint direct infringement through their activities in conjunction with the transplanters.
     
      
      . § 271(c). Whoever offers to sell or sells within the United States or imports into the United States a component of a patented machine, manufacture, combination or composition, or a material or apparatus for use in practicing a patented process, constituting a material part of the invention, knowing the same to be especially made or especially adapted for use in an infringement of such patent, and not a staple article or commodity of commerce suitable for substantial nonin-fringing use, shall be liable as a contributory infringer.
     